Molecular glue degraders and uses thereof

Novel compounds with specific functional groups address the limitations of existing pharmaceuticals by improving cancer and inflammatory disease treatment efficacy through targeted formulations for diverse administration.

SA1120261669A1Pending Publication Date: 2026-10-06INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +7
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
SA1120261669
Authority / Receiving Office
SA · SA
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-02-25
Publication Date
2026-10-06

AI Technical Summary

Technical Problem

Current pharmaceutical compounds lack efficacy in effectively treating cancer and inflammatory diseases, particularly due to limitations in targeting specific cellular pathways and causing adverse side effects.

Method used

Development of novel compounds with specific functional groups, such as Cx-Cy alkyl, cyclic alkyl, heterocyclic alkyl, and aryl groups, which are selectively substituted to enhance therapeutic targeting and minimize side effects, formulated into pharmaceutical preparations for various administration routes.

Benefits of technology

The novel compounds demonstrate improved therapeutic efficacy in cancer treatment and inflammatory disease management by enhancing cellular targeting and reducing adverse reactions, offering a range of administration methods for personalized dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 071A413D-7890-4D50-9504-4ACE2360C97C
    Figure 071A413D-7890-4D50-9504-4ACE2360C97C
  • Figure 0C66E7BE-44B5-4EF9-A7E1-069F991C105B
    Figure 0C66E7BE-44B5-4EF9-A7E1-069F991C105B
  • Figure 0F614989-ACFB-43EC-B8BE-BA6C3C518093
    Figure 0F614989-ACFB-43EC-B8BE-BA6C3C518093
Patent Text Reader

Abstract

The current investigation concerns pyrazol[1,5-a][1,3,5]triazine derivatives and their applications. Specifically, it concerns the (I) formulation compounds of 2,8-halogen-N4-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-2,4-diamine substitution, pharmaceutical compositions containing these compounds, and the preparation and applications of these five compounds, particularly as molecular glue degraders. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Definitions As used in this document, the term "Cx-Cy alkyl," whether alone or as part of another substituent, refers to a linear or branched alkyl functional group containing x to y carbon atoms, preferably 1 to 12 carbon atoms, and even more preferably 1 to 6 carbon atoms. Suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, pentyl and its isomers (such as n-pentyl and isopentyl), and hexyl and its isomers (such as n-hexyl and isohexyl). As used in this document, the term "cyclic alkyl C3-C12" refers to a saturated or unsaturated cyclic group containing 3 to 12 carbon atoms, preferably 3 to 6. A cyclic alkyl may contain a single ring or multiple rings fused together. It may also include helical rings. Suitable cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. As used in this document, the term "halogen" refers to a fluoro (-F), chloro (-Cl), bromo (-Br), or iodo (-I) group. As used in this document, the term "C1-Cx heterocyclic alkyl" refers to a straight or branched hydrocarbon chain consisting of one to x carbon atoms, preferably one to twelve carbon atoms, and even more preferably one to six carbon atoms, and at least one heterocyclic atom, preferably one to three selected heterocyclic atoms from the group consisting of oxygen (O), nitrogen (N), silicon (Si), and sulfur (S), where the nitrogen and sulfur atoms can be selectively oxidized (e.g., sulfoxide or sulfone), and where the nitrogen heterocyclic atom can be selectively tetragonalized. The heterocyclic atom(s) of O, N, and S can be placed at any internal position within the heterocyclic alkyl group or at the position where the alkyl group is bonded to the rest of the molecule. As used in this document, the terms “C1-Cx alkylene”, used alone or as part of another alternative, refer to a divalent saturated hydrocarbon group, with a straight or branched chain containing 1 to x carbon atoms, preferably 1 to 12 carbon atoms, and better still 1 to 6. As used in this document, the term "C1-Cx heteroalkyne" refers to a divalent heteroalkyne as defined herein. For heteroalkyne groups, the heteroatoms can occupy one or both ends of the chain. As used in this document, the term "aryl containing 6 to 10 cyclic atoms" refers to a polyunsaturated aromatic hydrocarbyl group containing one or more aromatic rings fused together, with 6 to 10 cyclic atoms, at least one of which is aromatic. The aromatic ring may optionally include one or two additional rings (cyclic alkyl, heterocyclic group, or heterocyclic aryl as defined in this document) fused to it. Suitable aryl groups include phenyl, naphthyl, and phenyl fused to a heterocyclic group, such as benzopyranyl, benzodioxolyl, benzodioxanyl, and the like. As used in this document, the term "heterocyclic aryl group containing 5 to 10 cyclic atoms" refers to a polyunsaturated aromatic ring system containing one or more aromatic rings fused together or covalently linked, with 5 to 10 atoms, where at least one ring is aromatic and at least one cyclic atom is a heteroatomoid chosen from N, O, and S. The heteroatoms can be selectively oxidized, and the heteroatoms can be selectively tetramerized. These rings can be combined into an aryl ring, a cyclic alkyl ring, or a heterocyclic group ring.Unrestricted examples of this heterocyclic aryl group include: furanyl, thiophenyl, pyrrolilyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxynyl, thiazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiaphenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, purinyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, cinolinyl, quinazolinyl, and quinoxalinyl. As used in this document, the term "heterocyclic group containing 3 to 10 cyclic atoms" refers to a saturated or unsaturated cyclic group containing 3 to 10 cyclic atoms, preferably 5 to 10, where at least one cyclic atom is a heteroatom chosen from N, O, and S. The heteroatoms of nitrogen and sulfur can be selectively oxidized, and the heteroatoms of nitrogen can be selectively tetragonal. The heterocyclic group can include fused or ligand-connected rings as well as helical rings. Examples of heterocyclic groups include, but are not limited to, tetrahydropyridyl, piperidinyl, morpholinyl, tetrahydrofuranyl, tetrahydrothenyl, piperazinyl, 1-azepanyl, imidazolinyl, 1,4-dioxanyl, and the like. As used in this document, the term “organyl group” refers to any organic alternative group, regardless of its functional type, that has one free valence in the carbon atom. As used in this document, the term "selectively substituted" may refer to groups that can be substituted by one or more of the following independently chosen substitutions: C1-C20 alkyl, C1-C20 heterocyclic alkyl, aryl containing 6 to 10 cyclic atoms, C3-C8 cyclic alkyl, 3 to 10 cyclic alkyl, 5 to 10 cyclic aryl, -X, -R', -O-, -OR', =O, -SR', -S-, -NR'2, -NR'3, =NR', -CX3, -CN, -OCN, -SCN, -NCS, -NO, -NO2, =N2, -NRC(=O)R', -C(=O)R'; -C(=O)NR'2, -SO3-, -SO3H, -S(=O)2R', -OS(=O)2OR', -S(=O)2NR', -S(=O)R', -C(=O)R', -C(=S)R', -CO2R', -CO2, -C(=S)OR', C(=O)SR', C(=S)SR', C(=O)NR'2, C(=S)NR'2, C(=NR')NR'2, and any combination thereof, where each X is independently a halogen: -F, -CI, -Br, or -I; Each R' independently consists of -H, -C1-C20 alkyl, -C6-C10 aryl, C3-C8 cyclic alkyl, a heterocyclic alkyl containing 3 to 10 cyclic atoms, or a heterocyclic aryl containing 5 to 10 cyclic atoms. In the current analysis, the dotted link represents the point of connection of one part to the rest of the molecule. Several application models for this detection are described in this document. It will be acknowledged that the features identified in each application model can be combined with other specific features to provide further application models. The current disclosure includes the compounds listed in the current disclosure, synthesized compounds, mirror isomers, differential isomers, racemates or mixtures thereof, their hydrates, esters, solutes or pharmaceutically acceptable salts. The term "pharmaceuticalally acceptable salts" refers to salts that retain the biological activity and properties of the compounds identified in this disclosure and are not normally biologically or otherwise undesirable. In many cases, the compounds identified in this disclosure are capable of forming acids and / or basic salts due to the presence of amino and / or carboxyl groups or similar groups. Pharmaceuticalally acceptable acid addition salts can be formed using organic and / or inorganic acids. Pharmaceuticalally acceptable base addition salts can be formed using organic and / or inorganic bases. In many cases, the compounds identified are capable of forming esters due to the presence of carboxyl groups. These esters include C1-C6 alkyl esters. Any form included in this invention is intended to represent unlabeled forms as well as forms of compounds labeled with isotopes, such as compounds labeled with deuterium or compounds labeled with 14C. Compounds with formula I The current detection provides a compound with the formula (I). (I) where The halogen is a halogen atom, preferably Br; R1 is chosen from the group consisting of H and the alkyl C1-C6, and the aforementioned alkyl is optionally substituted; R2 is chosen from a group consisting of C1-C20 alkyl groups, C1-C20 heteroallic groups, aryls containing 6 to 10 cyclic atoms, C3-C8 cyclic alkyl groups, heteroallic groups containing 3 to 10 cyclic atoms, heteroallic groups containing 5 to 10 cyclic atoms, any combination thereof, the aforementioned alkyl group, heteroallic groups, aryls, cyclic alkyl groups, heteroallic groups, and a heteroallic group that is optionally substituted, preferably by one or more substituents chosen from a group consisting of -OH, =O, C1-C12 alkyl groups, C1-C12 heteroallic groups, C3-C6 cyclic alkyl groups containing 5 to 10 cyclic atoms, and aryls containing 6 to 10 cyclic atoms. Cyclocyclic, heterocyclic aryl containing 5 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl groups; Alternatively, R1 and R2, along with the N atom to which they are bonded, form a heterocyclic alkyl containing 3 to 10 heteroatoms, or a heteroryl containing 5 to 10 cyclic atoms. The aforementioned heterocyclic alkyl is selectively substituted, preferentially by one or more substituents chosen from -OH, =O, C1-C12 alkyl, C1-C12 heterocyclic alkyl, C3-C6 cyclic alkyl, a heterocyclic group containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 homoatoms, a heteroryl containing 5 to 10 cyclic atoms, -(C1-C12 alkyl)-(C3-C8 cyclic alkyl), and -(C1-C12 alkyl)-(a heterocyclic alkyl containing (3 to 10 cyclic atoms), and (C1-C12 alkyl) (heterocyclic aryl containing 5 to 10 cyclic atoms), and (C1-C12 alkyl) (aryl containing 6 to 10 cyclic atoms), and (C3-C8 cyclic alkyl) (C1-C12 heterocyclic alkyl), and (3 to 10 cyclic alkyl) (C1-C12 heterocyclic alkyl), (heterocyclic aryl containing 5 to 10 cyclic atoms) (C1-C12 heterocyclic alkyl), and (aryl containing 6 to 10 cyclic atoms) (C1-C12 heterocyclic alkyl) --NR'R''; and R' and R'' are selected independently from H and alkyl C1-C6; Salts that are acceptable pharmaceutically and their solutes. According to one applied model, a halogen is a halogen atom, preferably Br; R1 is chosen from the group consisting of H, and alkyl C1-C6; R2 is chosen from a group consisting of C1-C12 alkyl groups, C1-C12 heteroalkyl groups, aryls containing 6 to 10 cyclic atoms, C3-C8 cyclic alkyl groups, heteroalkyl groups containing 3 to 10 cyclic atoms, heteroalkyl groups containing 5 to 10 cyclic atoms, any combination thereof, the aforementioned alkyl group, heteroalkyl groups, aryls, cyclic alkyl groups, heteroalkyl groups, and heteroalkyl groups that are optionally substituted, preferably by one or more substituents chosen from a group consisting of -OH, =O, C1-C12 alkyl groups, C1-C12 heteroalkyl groups, C3-C6 cyclic alkyl groups containing 5 to 10 cyclic atoms, and heteroalkyl groups containing 6 to 10 cyclic atoms. Cyclic, and -NR'R''; and R' and R'' are selected independently from H and alkyl C1-C6; Or R1 and R2, along with the N atoms to which they are bonded, form a heterocyclic alkyl containing 3 to 10 cyclic atoms, or a heterocyclic aryl containing 5 to 10 cyclic atoms. The heterocyclic alkyl and the heterocyclic aryl are optionally substituted, preferentially by one or more substituents chosen from -OH, =O, and C1-C12 alkyl, or C1-C12 heterocyclic alkyl, C3-C6 alkyl, a cyclic group containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, a heterocyclic aryl containing 5 to 10 cyclic atoms, -(C1-C12 alkyl)-(C3-C8 alkyl cyclyl), and -(C1-C12 alkyl)-(a heterocyclic alkyl containing 3 to (10 cyclic atoms), and -(C1-C12 alkyl)-(heterocyclic aryl containing 5 to 10 cyclic atoms), and -(C1-C12 alkyl)-(aryl containing 6 to 10 cyclic atoms), and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl; Salts that are acceptable pharmaceutically and their solutes. A halogen is a halogen atom, such as fluorine, chlorine, bromine, or iodine. For example, a halogen can be either fluorine or bromine. Bromine is the preferred halogen. According to one applied model, R2 is chosen from a group consisting of C1-C12 heterocyclic alkyl groups, aryls containing 6 to 10 cyclic atoms, C3-C8 cyclic alkyl groups, heterocyclic alkyl groups containing 3 to 10 cyclic atoms, -(C1-C12)-(C3-C8 cyclic alkyl groups), -(C1-C12)-(heterocyclic alkyl groups containing 3 to 10 cyclic atoms), a given alkyl group, a heterocyclic alkyl group, an aryl group, a cyclic alkyl group, and a heterocyclic alkyl group that is optionally substituted, preferentially by one or more substituents chosen from a group consisting of -OH, =O, C1-C12 alkyl groups, C1-C12 heterocyclic alkyl groups, C3-C6 cyclic alkyl groups, and a heterocyclic group containing On 5 to 10 cyclic atoms, and aryl contains 6 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl. According to one applied model, R2 consists of at least one nitrogen atom. According to one applied model, R1 and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic alkyl group containing 3 to 10 cyclic atoms and including at least two N atoms, where the heterocyclic alkyl is optionally substituted by one or more substituents preferred from the C1-C12 heterocyclic alkyl group, and a heterocyclic group containing 5 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from the H and C1-C6 alkyl groups. According to one applied model, the halogen is bromine, R1 is H, and R2 is a C3-C8 cyclic alkyl substituted with -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl. According to one applied model, the compound has the formula (II): (II) where L is a bond chosen from a ligand, a C1-C20 alkylene, a C1-C20 heteroalkyne, an arylene containing 6 to 10 cyclic atoms, a C3-C8 cyclic alkylene, a heteroalkyne containing 3 to 10 atoms, a heteroarylene containing 5 to 10 cyclic atoms, any combination of the above, the aforementioned alkylene, a heteroalkylene, an arylene, a cyclic alkylene, a heteroalkylene, a heteroalkylene, a heteroalkylene that is selectively substituted, preferentially by one or more substituents from the group consisting of -OH, and=O, a C1-C12 alkylene, a C1-C12 heteroalkyle, a C3-C6 cyclic alkylene, and a heteroalkyne group consisting of 5 to 10 atoms. Cyclocyclic, and aryl contains 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and alkyl C1-C6, R3 is chosen from the group consisting of H, and the alkyl C1-C6, R4 is chosen from the group consisting of H, and the alkyl C1-C6. According to one applied model, the compound has the formula (III). (III) where The A ring is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a given heteroaryl aryl and a heterocyclic alkyl that are optionally substituted, preferentially by one or more substituents chosen from the group consisting of -OH, and=O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cyclic alkyl, a heterocyclic alkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl; L is a bond chosen from a ligand, a C1-C12 alkylene, a C1-C12 heteroalkylene, an arylene containing 6 to 10 cyclic atoms, a C3-C8 cyclic alkylene, a heteroalkylene containing 3 to 10 atoms, a heteroalkylene containing 5 to 10 cyclic atoms, any combination of the above, the aforementioned alkylene, the heteroalkylene, an arylene, a cyclic alkylene, a heteroalk ... 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and alkyl C1-C6; R3 is chosen from the group consisting of H, and the alkyl C1-C6, R4 is chosen from the group consisting of H, and the alkyl C1-C6. According to one applied model, the compound has the formula (IV) (IV) where The A ring is a heterocyclic alkyl containing 3 to 10 cyclic atoms, or a heterocyclic aryl containing 5 to 10 cyclic atoms, and a given heterocyclic aryl and a heterocyclic alkyl that are optionally substituted, preferentially by one or more substituents chosen from the group consisting of -OH, =O, C1-C12 alkyl, C1-C12 heterocyclic alkyl, C3-C6 cyclic alkyl, a heterocyclic alkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl. The B ring is a heterocyclic alkyl containing 3 to 10 cyclic atoms, or a heterocyclic aryl containing 5 to 10 cyclic atoms, and a given heterocyclic aryl and a heterocyclic alkyl that are optionally substituted, preferentially by one or more substituents chosen from the group consisting of -OH, =O, C1-C12 alkyl, C1-C12 heterocyclic alkyl, C3-C6 cyclic alkyl, a heterocyclic alkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl. L is a bond chosen from a ligand, a C1-C12 alkylene, a C1-C12 heteroalkylene, an arylene containing 6 to 10 cyclic atoms, a C3-C8 cyclic alkylene, a heteroalkylene containing 3 to 10 atoms, a heteroalkylene containing 5 to 10 cyclic atoms, any combination of the above, the aforementioned alkylene, the heteroalkylene, an arylene, a cyclic alkylene, a heteroalk ... 10 cyclic atoms, and -NR'R"; R' and R' are chosen independently from the H and alkyl C1-C6; and R3 is chosen from the group consisting of H, and the alkyl C1-C6. According to one applied model, the compound has the formula (V) (V) where The B ring is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a given heteroaryl aryl and a heterocyclic alkyl that are optionally substituted, preferentially by one or more substituents chosen from the group consisting of -OH, and=O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cyclic alkyl, a heterocyclic alkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl; L is a bond chosen from a ligand, a C1-C12 alkylene, a C1-C12 heteroalkylene, an arylene containing 6 to 10 cyclic atoms, a C3-C8 cyclic alkylene, a heteroalkylene containing 3 to 10 atoms, a heteroalkylene containing 5 to 10 cyclic atoms, any combination of the above, the aforementioned alkylene, the heteroalkylene, an arylene, a cyclic alkylene, a heteroalk ... 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and alkyl C1-C6; and R3 is chosen from the group consisting of H, and the alkyl C1-C6. According to one applied model, R2 is chosen from a group consisting of C1-C12 heteroalkyl groups, aryls containing 6 to 10 cyclic atoms, C3-C8 cyclic alkyl groups, heteroalkyl groups containing 3 to 10 cyclic atoms, -(C1-C12)-(C3-C8 cyclic alkyl groups), -(C1-C12)-(heterocyclic alkyl groups containing 3 to 10 cyclic atoms), a given alkyl group, a heteroalkyl group, an aryl group, a cyclic alkyl group, and a heterocyclic alkyl group that is optionally substituted, preferentially by one or more substituents chosen from a group consisting of -OH groups, C1-C12 alkyl groups, C1-C12 heteroalkyl groups, C3-C6 cyclic alkyl groups, and a heterocyclic group containing 5 to 10 cyclic atoms, and aryl contains 6 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl. According to one applied model, the choice is made using formula (I) from ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and. According to one applied model, a compound with formula (I) is a compound chosen from ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,. According to one applied model, a compound with formula (I) is a compound chosen from . According to one applied model, a compound with the formula (I) is a . The current disclosure also relates to a method for assembling one of the vehicles included in the disclosure. The compounds identified in the disclosure can be prepared using standard procedures in organic synthesis (chemical reactions, extraction, evaporation, precipitation, chromatography, filtration, crushing, crystallization, and the like) and analytical procedures familiar to those with ordinary analytical chemistry experience. Details of these reactions and techniques can be found in several treatises, including Richard Larock, *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*, 2nd ed. (2010), and the multi-volume series edited by Michael B. Smith and others, *Compendium of Organic Synthetic Methods* (1974 et seq.). The raw materials and reagents can be obtained commercially or prepared using the methods employed in the studies. The compound can be formulated as (I) as follows: Compound A can be prepared as described in WO2018195397. Compound A can be converted to compound B using phosphorus oxychloride first, followed by 4-(pyridine-2-yl)phenyl)methamine. Compound B is then oxidized to the corresponding sulfone C, for example, using metachloroperoxybenzoic acid. Finally, compound I can be prepared by nucleoaromatic substitution using the amine HNR1R2. This step can be carried out by heating the reaction mixture to a temperature between 100 and 180 °C, such as 140 °C. The same procedure can be used for compounds of formula (II), (III), (IV), and (V) using the corresponding amines. Pharmaceutical formulation The detection also relates to a pharmaceutical formulation containing a detection compound and at least one pharmaceutically acceptable carrier. Specifically, the current detection relates to a pharmaceutical formulation consisting of a compound with the formula (I) and at least one pharmaceutically acceptable carrier. As used in this document, "pharmaceuticalally acceptable carrier" includes any and all solvents, dispersing media, coatings, antibacterial and antifungal agents, absorption delaying and isotonic agents, and the like that are physiologically compatible. The pharmaceutical formulations mentioned in the disclosure may be formulated for topical, oral, intranasal, intraocular, intravenous, intramuscular, subcutaneous, and similar administration. For example, pharmaceutical formulations may take the form of tablets, pills, capsules, semi-solids, powders, sustained-release formulations, solutions, suspensions, emulsions, syrups, elixirs, sprays, or any other suitable formulations; and include at least one compound in accordance with this disclosure. Because of their ease of administration, tablets and capsules represent the most common form of oral dosage unit, and in this case, solid pharmaceutical carriers are clearly used. Tablets may be sugar-coated or enteric-coated using standard techniques. Tablets or capsules can be coated to provide a dosage form that offers the advantage of a prolonged effect. For example, a tablet or capsule may consist of an inner dosage component and an outer dosage component, the latter being a coating on top of the former. The two components can be separated by an enteric coating that resists dissolution in the stomach and allows the inner component to pass intact into the duodenum or delays its release. A variety of materials can be used for these enteric coatings, including several polymeric acids such as shellac, cetyl alcohol, and cellulose acetate. Detection compounds can also be delivered in the form of liposome delivery systems, such as small monolayer vesicles, large monolayer vesicles, and multilayer vesicles. Liposomes can be composed of a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholine. According to one applied model, pharmaceutical formulations contain carrier materials that are pharmacologically acceptable for oral formulation. In other specific application models, the carrier may be suitable for intravenous, intramuscular, subcutaneous, intravenous, spinal, or transdermal administration (e.g., by injection or infusion). In one application model, the carrier must be suitable for subcutaneous or intratumoral injection. Depending on the route of administration, the active compound may be encapsulated to protect it from acids and other environmental conditions that could inactivate it. Injectable formulations may also include one or more excipients, preservatives, solvents, diluents, etc. The form of pharmaceutical formulations, method of administration, dosage, and treatment regimen naturally depend on the condition to be treated, the severity of the disease, the patient's age, weight, gender, etc. Ideally, pharmaceutical formulations contain carrier substances that are pharmacologically acceptable for an injectable formulation. These substances may be, in particular, isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, and the like, or mixtures of these salts), or dry formulations, especially freeze-dried ones, which, when added to sterile water or physiological saline, as appropriate, allow the formation of injectable solutions. The doses used for administration can be adapted as a function of various variables, specifically as a function of the method of administration used, the relevant medical condition, or alternatively, the duration of treatment required. To prepare pharmaceutical formulations, an effective quantity of the compound may be dissolved or dispersed, according to the detection, in a carrier substance or aqueous medium acceptable to pharmaceuticals. Suitable pharmaceutical forms for injection include sterile aqueous solutions or dispersants; formulations containing sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders or lyophilized solutions for the improper preparation of sterile injectable solutions or dispersants. In all cases, the formulation must be sterile and sufficiently liquid to allow for easy administration by syringe. These materials must be stable under manufacturing and storage conditions and protected from contamination by microorganisms such as bacteria and fungi. Solutions of the active compounds can be prepared as a free base or pharmacologically acceptable salt in water appropriately mixed with a surfactant, such as hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, mixtures thereof, and oils. These preparations, under normal storage and usage conditions, contain a preservative to prevent the growth of microorganisms. The compounds listed in the disclosure may be formulated in neutral or salt forms. Pharmaceuticalally acceptable salts include acid addition salts (formed from free amino groups) derived from inorganic acids such as hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, and mandelic acids, and the like. Salts formed from free carboxyl groups may also be derived from inorganic bases such as sodium, potassium, ammonium, calcium, or ferric hydroxides, and organic bases such as isopropylamine, trimethylamine, histidine, procaine, and the like. The carrier material can be a solvent or dispersing medium containing, for example, water, ethanol, polyolefins (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), suitable mixtures thereof, or vegetable oils. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of the dispersing medium, and by using surfactants. Microbiological activity can be inhibited by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and similar substances. In many cases, it is preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of injectable formulations can be achieved by using formulations of absorption delaying agents, for example, aluminum monostearate and gelatin. Sterile injectable solutions are prepared by combining the required amount of active ingredients in a suitable solvent with the other ingredients listed above, as needed, and then performing sterilization with filtration. Dispersions are generally prepared by combining various sterile active ingredients in a sterile carrier containing a basic dispersing medium with the other required ingredients mentioned above. For sterile powders required to prepare sterile injectable solutions, the preferred preparation methods are pneumatic drying and freeze-drying techniques, which yield a powder of the active ingredient and any other required additives from the previously filtered sterile solution. Consideration is also being given to preparing more concentrated or higher-strength solutions for direct injection, since the use of dimethyl sulfoxide as a solvent is expected to result in very rapid penetration, delivering high concentrations of active agents to a small tumor area. Upon formulation, the solutions will be administered in a manner consistent with the dosage structure and in a therapeutically effective quantity. The formulations are readily available in a variety of dosage forms, such as the injectable solutions described above; drug-release capsules and similar formulations can also be used. For administration by injection in an aqueous solution, for example, the solution must be appropriately stored if necessary, and an isotonic liquid diluent must first be administered with sufficient saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this regard, the sterile aqueous media that can be used will be known to those experienced in the field in light of the current disclosure. For example, a single dose may be dissolved in 1 mL of isotonic sodium chloride solution and added to 1000 mL of fluid for subcutaneous injection or injected at the proposed infusion site (see, for example, Remington's Pharmaceutical Sciences, 15th vol., pp. 1035–1038 and 1570–1580). Some variation in dosage will necessarily occur based on the condition of the study participant being treated. In all cases, the administrator will determine the appropriate dose for each individual study participant. The dosage used for administration can be tailored as a function of various variables, specifically as a function of the route of administration, the underlying medical condition, or, alternatively, the duration of treatment. It is important to note that appropriate dosages of compounds, and combinations containing such compounds, can vary from patient to patient. Determining the optimal dose generally involves balancing the level of therapeutic benefit against any risks or adverse side effects of the treatments described in this document. The chosen dosage level depends on a variety of factors, including, but not limited to, the activity of the specific compound, the route of administration, the time of administration, the rate of elimination of the compound, the duration of treatment, other drugs, compounds, and / or substances used concurrently, and the patient's age, sex, weight, general condition and health, and medical history. The amount of compound and the route of administration will ultimately be at the physician's discretion, although the dose will generally be intended to achieve local concentrations at the site of action that produce the desired effect without causing significant adverse or harmful side effects. For example, the dosage used for administration could be approximately 0.0001-5000 mg of the aforementioned compound for a study participant weighing approximately 50-70 kg. How to use The compounds listed in this disclosure exhibit valuable pharmacological properties, as demonstrated in the in vitro and in vivo tests presented in the examples, and are therefore suitable for therapeutic use, particularly in cancer treatment. The disclosure also pertains to a compound listed in the disclosure for medicinal use. Specifically, the disclosure pertains to a compound with the formula (I), (II), (III), (IV), or (V) for medicinal use. Specifically, the compounds mentioned in this disclosure, such as those with the formula (I), (II), (III), (IV), or (V), are useful in the prevention or treatment of cancer or inflammatory diseases. This discovery relates to a method for treating cancer or an inflammatory disease. This method involves giving a study participant who needs it, preferably a human, a therapeutically effective amount of (i) A compound included in the disclosure, Or (ii) a pharmaceutical formulation containing this compound as described in this document. As used in this document, the term “treatment” includes reversing, alleviating, inhibiting the development of, preventing, or reducing the likelihood of developing a disease, disorder, or condition to which that term applies, or one or more of its symptoms or manifestations. The term “prevention” refers to preventing the occurrence of a disease, disorder, or condition, or one of its symptoms or manifestations, or the worsening of its severity. Accordingly, the compounds currently identified may be given prophylactically to prevent or reduce the occurrence or recurrence of a disease, disorder, or condition. As used in this document, the term "therapeutically effective amount" of a compound refers to an amount of the compound that would elicit a biological or medical response in a study participant, for example, improving symptoms, alleviating conditions, slowing or delaying disease progression, or preventing disease. The disclosure also relates to the use of a compound included in the disclosure, preferably a compound with the formula (I), to manufacture a drug for treating cancer. The disclosure also relates to a compound mentioned in the disclosure for use in a method for treating cancer. As used in this document, the term "cancer" has its general meaning in this field and includes an abnormal condition or situation characterized by the rapid growth of proliferating cells. This term is intended to encompass all types of malignant tumors or tumor-causing processes, metastatic tissues, cells, tissues, or organs that have been malignantly transformed, regardless of histological type or stage of invasion. The term cancer includes malignant tumors affecting various body systems, such as those affecting the lung, breast, thyroid gland, lymphatic system, digestive system, and genitourinary system, as well as adenocarcinomas, which include malignant tumors such as most colon cancers, renal cell carcinoma, prostate and / or testicular cancers, non-small cell lung cancer, small bowel cancer, and esophageal cancer. This finding also relates to a compound included in the report that is being used in a method for treating inflammatory disease. Inflammatory disease can be caused by bacteria, viruses, prions, parasites, or fungi, or it may be caused by irritants, trauma, metabolic, allergic, autoimmune, or idiopathic factors. The inflammatory disease can be selected from a group that includes or consists of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of the blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory skin diseases, uveitis, and inflammatory diseases of the larynx. The abbreviation "AcOH" refers to acetic acid; the abbreviation "BOC" refers to tert-butyloxycarbonyl; the abbreviation "Boc2O" refers to di-tert-butyl dicarbonate; the abbreviation "ACN" refers to acetonitrile; the abbreviation "DCM" refers to dichloromethane; the abbreviation "DIPEA" refers to N,N-diisopropylethylamine; the abbreviation "DMAP" refers to 4-dimethylaminopyridine; the abbreviation "DMF" refers to dimethylformamide; "DMSO" refers to dimethyl sulfoxide; "Et2O" refers to diethyl ether; the abbreviation "EtOAc" refers to ethyl acetate; "EtOH" refers to ethanol; the abbreviation "MCPBA" refers to 3-chloroperoxybenzoic acid; the abbreviation "MeOH" refers to methanol; and the abbreviation "NBS" refers to N-bromosuccinimide. The abbreviation "Py" refers to pyridine; the abbreviation "RT" refers to room temperature; and the abbreviation "TFA" refers to 2,2,2-trifluoroacetic acid; Examples Example 1: Synthesis of the 2,8-halogen-N4-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine substituted family of compounds Materials and general methods of organic synthesis All solvents, reagents, and active pharmaceutical ingredients were obtained from reputable commercial sources (Sigma-Aldrich, Fluorochem, TCI Chemicals, Acros Organics, Alfa Aesar, Enamine, Thermo Fisher, Carbosynth, WuXi AppTec, MedChemExpress) and used without further purification unless otherwise stated. Anhydrous solvents were purchased from Sigma-Aldrich. Unless otherwise stated, all chemical reactions were performed at room temperature in an inert argon-filled medium. Compounds were obtained with >95% HDC purity at 254 nm unless otherwise stated. Liquid nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Fourier 300HD or Bruker AVANCE III HD400 spectrometer, using the peak of the residual solvent for calibration. Interchangeable NHs were not described. Mass spectrometry analysis was performed either in-house or by the Centre Commun de Spectrométrie de Masse (CCSM) of the CNRS Institute at University Claude Bernard Lyon 1. Normal-phase flash chromatography was performed on either Teledyne Isco CombiFlash® Rf200 or CombiFlash®NextGen 300 or Biotage® Flash System systems, using Macherey-Nagel Chromabond® flash cartridges (40–63 µm). Reverse-phase chromatography was performed using Biotage® Sfär C18 Duo 100 angstrom 30 µm cartridges, a Luna Omega Polar C18 column (21 × 150 mm; 5 µm), or an Agilent 1100 dual-preparation high-performance liquid chromatography system. Chemical reactions were monitored, compounds were characterized, and analyzed respectively by thin-layer chromatography using 40-63 μm pre-coated silica gel (Macherey-Nagel), or high-performance liquid chromatography with a UV detector (Agilent 1100 systems), or high-performance liquid chromatography with a UV detector and mass spectrometer (Thermo UltiMate 3000 HPC system with Bruker Impact II™ Q-ToF mass spectrometer or Agilent 1260 HPC system with Bruker MicrOTOF-QII mass spectrometer). High-performance liquid chromatography (HPLC) method 1: An Agilent 1100 HPLC system with a DAD reagent. Mobile phase A was water + 0.1% trifluoroacetic acid, and mobile phase B was acetonitrile. The column was an Agilent Zorbax SB-Aq with dimensions of 4.6 x 150 mm and a particle size of 5 µm (at room temperature). The linear gradient was from 0% in phase B to 50% in phase B in 30 minutes, followed by a 5-minute holding period at 50% in phase B. The flow rate was 1.0 mL / min. High-performance liquid chromatography (HPLC) method 2: An Agilent 1100 HPLC system with a DAD detector. Mobile phase A was water + 0.1% trifluoroacetic acid, and mobile phase B was acetonitrile. The column was an Agilent Poroshell 120 EC-C18 with dimensions of 3.0 × 50 mm and a particle size of 2.7 μm (at room temperature). The linear gradient was from 5% to 80% in phase B over 9 minutes, followed by a 1-minute holding period at 80% in phase B. The flow rate was 0.8 mL / min. High-performance liquid chromatography (HPLC) method 3: An Agilent 1100 HPLC system with a DAD reagent. Mobile phase A was water + 0.1% trifluoroacetic acid, and mobile phase B was acetonitrile. The column was an Agilent Poroshell 120 EC-C18 with dimensions of 3.0 × 50 mm and a particle size of 2.7 μm (room temperature). The linear gradient was from 5% to 80% in phase B over 20 minutes, followed by a 2-minute holding period at 80% in phase B. The flow rate was 0.8 mL / min. High-performance liquid chromatography (HPLC) method 4: Thermo UltiMate 3000 HPC system + Bruker Impact II™ Q-ToF mass spectrometer. Mobile phase A was water + 0.1% formic acid, and mobile phase B was acetonitrile + 0.1% formic acid. The column used was an Agilent PLRP-S with a porosity of 1000 angstroms and dimensions of 2.1 x 150 mm, with a particle size of 8 µm (80°C). The linear gradient was from 10% in phase A to 50% in phase B in 25 minutes, with a flow rate of 0.4 mL / min. Detection was monitored by UV light at 280 nm. The Q-ToF mass spectrometer was used in the range of m / z from 500 to 3500 (ESI+). The data were decompiled using the MaxEnt algorithm built into the Bruker Compass® software. High-performance liquid chromatography (HPLC) Method 5 (Preparation Method): A biphasic eledyne [A1]Isco CombiFlash® Rf200 medium-pressure liquid chromatography system equipped with a DAD reagent. Mobile phase A was water + 0.1% trifluoroacetic acid, and mobile phase B was acetonitrile. Reusable Biotage® Star C18 Duo cartridges with a porosity of 100 angstroms and a particle size of 30 µm (30 g) were used. The linear gradient was from 10% in phase B to 50% in phase B in 35 minutes, followed by a 5-minute holding period at 50% in phase B. The flow rate was 25 mL / min. High-performance liquid chromatography (HPLC) Method 6 (Preparation Method): An Agilent 1100 dual-preparation HPLC system with a dual-loop autoinjector, DAD detector, and component collector was used. Mobile phase A was water + 0.1% trifluoroacetic acid, and mobile phase B was acetonitrile. The column was a Waters SunFire C18 OBD preparation column with a porosity of 100 angstroms, 5 µm, and dimensions of 19 × 250 mm (room temperature). The linear gradient was from 10% in phase B to 60% in phase B in 40 minutes, followed by a 5-minute holding period at 60% in phase B. The flow rate was 25 mL / min. 1.1) Composition of compound 2384 Composition of compound I The compound 8-bromo-2-(methylthio)pyrazol[1,5-a]-1,3,5-triazine-4(3H)-one [CAS 54346-35-9] (compound I) was prepared as described in WO2018195397 with minor modifications. To 2-(methylthio)pyrazol[1,5-a]-1,3,5-triazine-4(3H)-one (3.0 g, 16.46 mmol) in dimethylformamide (30 mL), NBS (2.51 g, 14.10 mmol) was added in small increments over 5 minutes, maintaining the temperature between 8 and 10 °C. The mixture was held for 30 minutes at 0 °C and concentrated under vacuum. The resulting solid was dispersed in ethanol (20 mL), filtered, and washed with ethanol (5 mL × twice). 3.09 g (84% yield) of bromo derivative was obtained as a white solid after drying. 1H NMR (300 MHz, dimethyl sulfoxide) δ 13.07 (s, 1H), 8.12 (s, 1H), 2.57 (s, 3H). High-performance liquid chromatography-2, retention time = 4.64 min. Composition of compound II It was prepared from compound I,4-(pyridine-2-yl)phenyl)methamine (the free base was obtained by extracting dichloromethane from a basic aqueous solution at pH 9–10 of the commercial hydrochloride salt CAS1498333-87-1). To a purified solution of 8-bromo-2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one (compound I) (0.685 g, 2.62 mmol), diisopropylethylamine (0.914 mL, 2 equiv), and N-methylmorpholine (0.001 mL, 0.005 equiv) in acetonitrile (4.6 mL), POCl3 (0.318 mL, 1.3 equiv) was added at 0 °C. The mixture was then heated to room temperature and stirred for 1 hour. To the resulting suspension, (4-(pyridine-2-yl)phenyl)methamine (0.725 g, 1.5 equiv) was added at 0 °C, followed by diisopropyl ethylamine (0.457 mL, 1 equiv). The mixture was briefly filtered before being precipitated again. After stirring overnight at room temperature, the solid was filtered and washed with acetonitrile (1 mL, twice), yielding 8-bromo-2-(methylthio)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.898 g, yield at 80%, high-performance liquid chromatography purity 94%, 254 nm (expected as a beige solid). MS m / z (ESI+): Calculated mass of compound C18H15BrN6S [M+H]+ = 427.03; Exp [M+H]+ = 427.0. HPC 2 method, retention time = 5.91 mins. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.66 (t, J = 6.2 Hz, 1H), 8.65 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.25 (s, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 8.0 Hz, 1H), 7.91 – 7.84 (m, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.35 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.74 (d, J = 6.2 Hz, 2H), 2.49 (s, 3H). MS m / z (ESI+): Calculated mass of compound C18H15BrN6S [M+H]+ = 427.0; Exp [M+H]+ = 427.0. Composition of compound III To 8-bromo-2-(methylthio)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (compound II) (0.896 g, 2.10 mmol) in dichloromethane (42 mL), 70% MCPBA (0.517 mg, 1.0 Eq) was added in fractions at 0 °C over 5 minutes. The mixture was stirred at 0 °C for 1 hour, then diluted with dichloromethane (250 mL) and washed with saturated aqueous NaHCO3 (50 mL, twice) followed by saline (30 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under vacuum to obtain the predicted sulfoxide III compound (0.920 g, 99% yield, HLC purity: 91%, 254 nm) as a near-white solid. MS m / z (ESI+): Calculated mass of compound C18H15BrN6OS [M+H]+ = 443.03; Exp [M+H]+ = 443.0. HLC2, retention time = 4.10 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 10.10 (s, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.45 (s, 1H), 8.10 – 7.99 (m, 2H), 7.94 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.8 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.79 (s, 2H), 2.83 (s, 3H). Composition of compound 2384 A mixture of 8-bromo-2-(methylsulfonyl)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (compound III) (0.262 g, 0.591 mmol) and trans-1,4-diaminocyclohexane (0.540 g, 8 equivalents) was heated for 30 minutes at 140 °C. After cooling to room temperature, it was fractionated between dichloromethane (20 mL) and saturated aqueous NaHCO3 (10 mL), then extracted using dichloromethane (20 mL × twice) and washed with saline (10 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under vacuum. The raw material was purified by silica gel chromatography (15 g) and followed by sequential filtration using 1% to 20% methanol in dichloromethane to obtain compound 2384 (0.150 g, yield 51%) as a white foam. MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.2. High-performance liquid chromatography (HPLC) 2, retention time = 3.84 mins. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.94–7.91 (m, 2H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.54 – 7.41 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.71 – 4.61 (m, 2H), 3.79 – 3.54 (m, 1H), 2.63 – 2.41 (m, 1H), 1.93 – 1.66 (m, 4H), 1.36 – 1.04 (m, 4H). 1.2) Composition of compound 2388 Intermediate compound IV synthesis The above-described 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine sulfoxide (Compound III) (0.300 g, 0.68 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate [CAS Reg. No. 87120-72-7] (3 equivalencies) were thoroughly mixed and heated for 35 minutes at 145 °C. The crude mixture was fractionated between dichloromethane (20 mL) and saturated NaHCO3 (10 mL), then extracted using dichloromethane (20 mL × twice) and washed with saline (10 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under vacuum. The raw material was purified by silica gel chromatography (15 g) using dichloromethane / methanol solvent: a graded concentration from 0 / 100 to 5 / 95 to obtain compound IV (0.288 g, yield 73%, high-performance liquid chromatography purity: 99% at 254 nm) as a beige solid (foam). MS m / z (ESI+): Calculated mass of compound C27H32BrN8O2 [M+H]+ = 579.18; Exp = 579.2. High-performance liquid chromatography method 2, retention time = 5.86 minutes. Composition of compound 2388 The compound IV, protected by a tri-butoxycarbonyl group, tri-butyl 4-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)piperidine-1-carboxylate (257 mg, 0.44 mmol), was reacted in dichloromethane (5 mL) with trifluoroacetic acid (1 mL) at room temperature for 30 minutes. The mixture was concentrated under vacuum, then dissolved in water and acidified with 1 M NaOH (pH 9–10). The mixture was then split between dichloromethane (20 mL) and saturated NaHCO3 (10 mL), extracted using dichloromethane (20 mL × twice), and washed with saline (10 mL). The organic layer was dried on Na2SO4, filtered, and concentrated under vacuum to obtain 8-bromo-N2-(piperidine-4-yl)-N4-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine (compound 2388) (0.189 g, 88% yield) as a white foam. MS m / z (ESI+): Calculated mass of compound C22H24BrN8 [M+H]+ = 479.1; Exp = 479.1. High-performance liquid chromatography-2, retention time = 3.70 min.1H NMR (300 MHz, CDCl3) δ 8.69 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 7.99 (d, J = 8.3 Hz, 2H), 7.79 – 7.69 (m, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.23 (ddd, J = 6.8, 4.8, 1.8 Hz, 1H), 6.91 – 6.55 (m, 1H), 5.28 – 4.91 (m, 1H), 4.79 (swide, 2H), 4.20 – 3.80 (m, 1H), 3.21 – 2.99 (m, 2H), 2.90 – 2.56 (m, 2H), 2.20 – 1.83 (m, 2H), 1.48 – 1.27 (m, 2H). 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 7.0 Hz, 2H), 7.96–7.89 (m, 2H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.53–7.42 (m, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.77–4.57 (m, 2H), 3.95–3.61 (m, 1H), 2.93 (s, 2H), 2.62–2.5 (m, 2H), 1.90–1.56 (m, 2H), 1.46 – 1.12 (m, 2H). 1.3 Composition of compound 2568 The intermediate compound tri-butyl(co-4-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)hexylcyclocarbamate It was prepared from N-tert-butoxycarbonyl-coupled-1,4-chlorohexanediamide [CAS Reg. No. 177906-48-8] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (Compound III) (0.100 g, 0.226 mmol) described above using the same protocol as described above for Compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a beige solid (foam) (0.113 g, yield 84%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.2. High-performance liquid chromatography method 2, retention time = 5.99 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.0 Hz, 2H), 7.96–7.90 (m, 2H), 7.86 (td, J = 7.7, 1.8 Hz, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 6.61 (s, 1H, NHBoc), 4.78–4.60 (m, 2H), 3.89–3.68 (m, 1H), 3.39 (s, 1H), 1.82– 1.41 (m, 8H), 1.37 (s, 9H). Composition of compound 2568 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.085 g, 0.143 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2568 was obtained as a white foam (0.069 g, 98% yield). MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.1. High-performance liquid chromatography-2, retention time = 3.85 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 7.9 Hz, 2H), 7.96 – 7.89 (m, 2H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 8.06 – 8.01 (m, 2H), 2.85 (s, 1H), 1.82 – 1.38 (m, 8H) 1.4 Composition of compound 2584 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group (4-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)phenyl)carbamate It was prepared from tert-butyl(4-aminophenyl)carbamate [CAS Reg. No. 71026-66-9] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.096 g, 0.217 mmol) described above using the same protocol described above for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a beige solid (foam) (0.087 g, yield 68%). MS m / z (ESI+): Calculated mass of compound C28H28BrN8O2 [M+H]+ = 587.15; Exp = 587.2. High-performance liquid chromatography-2, retention time = 6.84 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.52 (swidth, 1H, exch NH), 9.29 (swidth, 1H, exch NH), 9.19 (swidth, 1H, exch NH), 8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.10 – 8.03 (m, 3H), 7.95 (dt, J = 8.0, 1.2 Hz, 1H), 7.87 (ddd, J = 8.1, 7.3, 1.9 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.41 – 7.20 (m, 3H), 7.74 – 7.44 (m, 2H); 4.75 (d, J = 6.1 Hz, 2H). Composition of compound 2584 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.060 g, 0.102 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2584 was obtained as a white foam (0.046 g, 92% yield). MS m / z (ESI+): Calculated mass of compound C23H19BrN8 [M+H]+ = 487.10; Exp = 487.1. High-performance liquid chromatography-2, retention time = 4.20 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.19 (s, 2H, exch NH), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.3 Hz, 2H), 8.01 (s, 1H), 7.96 – 7.90 (m, 1H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.48 (d, J = 7.9 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 7.03 – 7.64 (m, 1H), 6.49 (d, J = 8.4 Hz, 2H); 4.79 (s, 2H, exch NH), 4.71 (s wide, 2H). 1.5 Compound composition 2559 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group (1-(8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)piperidine-4-yl)carbamate It was prepared from 4-(tri-butoxycarbonylamino)piperidine [CAS Reg. No. 73874-95-0] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (0.092 g, 0.208 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tri-butoxycarbonyl group was obtained as a foam (0.105 g, yield 87%). MS m / z (ESI+): Calculated mass of compound C27H31BrN8O2 [M+H]+ = 579.18; Exp = 579.2. High-performance liquid chromatography (HPLC) 2, retention time = 6.69 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.18 (t, J = 6.2 Hz, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.1, 7.2, 1.8 Hz, 1H), 7.50 (d, J = 8.3 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.66 (d, J = 6.1 Hz, 2H), 4.59 – 4.49 (m, 2H), 3.60 – 3.38 (m, 1H), 3.06 – 2.92 (m, 2H), 1.81 – 1.70 (m, 2H), 1.37 (s, 9H), 1.32 – 1.15 (m, 2H). Composition of compound 2559 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.100 g, 0.173 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2559 was obtained as a white foam (0.072 g, yield 87%). MS m / z (ESI+): Calculated mass of compound C22H23BrN8 [M+H]+ = 479.13; Exp = 479.1. High-performance liquid chromatography-2, retention time = 3.91 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.03 (d, J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.66 (s, 2H), 4.55–4.41 (m, 2H), 3.08–2.92 (m, (2H), 2.85 – 2.68 (m, 1H), 1.80 – 1.62 (m, 2H), 1.19 – 1.01 (m, 2H). The interchangeable NH and NH2 were not visible. 1.6 Composition of compound 2622 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group is 4-(1-(8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)piperidine-4-yl)piperazine-1-carboxylate It was prepared from 1,1-dimethylethyl 4-(4-piperidinyl)-1-piperazine carboxylate [CAS Reg. No. 205059-24-1] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (0.090 g, 0.203 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a foam (0.094 g, yield 71%). MS m / z (ESI+): Calculated mass of compound C31H38BrN9O2 [M+H]+ = 648.24; Exp = 648.2. High-performance liquid chromatography method 2, retention time = 5.29 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.19 (t, J = 6.1 Hz, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.98 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.85 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.32 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.71–4.56 (m, 4H), 3.29– 3.14 (m, 4H), 2.88 – 2.76 (m, 1H), 2.45 – 2.28 (m, 4H), 1.81 – 1.63 (m, 2H), 1.38 (s, 9H), 1.26 – 1.09 (m, 2H). Composition of compound 2622 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.090 g, 0.139 mmol) as described above in the procedure for synthesizing compound 2388, and purified by silica gel chromatography (1% to 40% methanol in dichloromethane). Compound 2622 was obtained as a white foam (0.029 g, 38% yield). MS m / z (ESI+): Calculated mass of compound C26H30BrN9 [M+H]+ = 548.19; Exp = 548.1. High-performance liquid chromatography method 2, retention time = 3.95 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.18 (bs, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.97 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.74–4.56 (m, 4H), 2.90–2.75 (m, 2H), 2.67 – 2.55 (m, 4H), 2.45 – 1.08 (m, 9H). 1.7 Composition of compound 2569 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group is 4-(((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)methyl)piperidine-1-carboxylate It was prepared from [(piperidine-4-yl)methyl]tributylcarbamic acid ester [CAS Reg. No. 135632-53-0] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.088 g, 0.199 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tributoxycarbonyl group was obtained as a colorless resin (0.108 g, 92% yield). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.2. High-performance liquid chromatography method 2, retention time = 5.82 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (d, J = 4.8 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97 – 7.81 (m, 3H), 7.46 (d, J = 8.1 Hz, 2H), 7.37 – 7.30 (m, 1H), 4.68 (s, 2H), 4.00 – 3.71 (m, 2H), 3.13 (d, J = 9.2 Hz, 2H), 2.73 – 2.60 (m, 1H), 1.81 – 1.23 (m, 13H), 1.11 – 0.83 (m, 2H). Composition of compound 2569 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.110 g, 0.185 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2569 was obtained as a colorless foam (0.075 g, yield 82%). MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.1. High-performance liquid chromatography-2, retention time = 3.62 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (dt, J = 4.9, 1.3 Hz, 1H), 8.04 (dt, J = 8.4 Hz, 2H), 7.96 (s, 1H), 7.93 (dt, J = 8.0, 1.2 Hz, 1H), 7.90 – 7.83 (m, 1H), 7.52 – 7.43 (m, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.69 (s, 2H), 3.24 – 3.09 (m, 5H), 2.83 – 2.68 – 2.56 (m, 2H), 1.89 – 1.55 (m, (2H), 1.38 – 1.11 (m, 2H). 1.8 Composition of compound 2560 The structure of the intermediate compound protected from the tert-butoxycarbonyl tert-butyl group is: ((1-(8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)piperidine-4-yl)methyl)carbamate It was prepared from [(piperidine-4-yl)methyl]tributylcarbamic acid ester [CAS Reg. No. 135632-53-0] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.077 g, 0.174 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tributoxycarbonyl group was obtained as a colorless foam (0.087 g, yield 84%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.2. High-performance liquid chromatography method 2, retention time = 6.89 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.14 (t, J = 6.2 Hz, 1H), 8.64 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 8.03 (d, J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.3, 1.8 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 6.87 (t, J = 5.9 Hz, 1H), 4.77 – 4.52 (m, 4H), 2.91 – 2.76 (m, 4H), 1.71 – 1.53 (m, 3H), 1.36 (s, 9H), 1.11 – 0.88 (m, 2H). Composition of compound 2560 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.083 g, 0.140 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2560 was obtained as a white foam (0.057 g, yield 83%). MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.1. High-performance liquid chromatography-2, retention time = 4.17 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.97 (s, 1H), 7.93 (dt, J = 8.1, 1.3 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.73–4.57 (m, 4H), 2.92–2.76 (m, 2H), 2.66–2.54 (m, 2H), 1.79 – 1.62 (m, 2H), 1.62 – 1.47 (m, 1H), 1.09 – 0.88 (m, 2H). 1.9 Composition of compound 2606 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group is 3-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)piperidine-1-carboxylate It was prepared from 1-piperidine carboxylic acid 3-amino-, 1,1-dimethyl ethyl ester [CAS Reg. No. 184637-48-7] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.085 g, 0.192 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a white solid (foam) (0.075 g, yield 67%). MS m / z (ESI+): Calculated mass of compound C27H31BrN8O2 [M+H]+ = 579.18; Exp = 579.2. High-performance liquid chromatography method 2, retention time = 6.15 minutes. Composition of compound 2606 (raceme) The compound protected by the tri-butoxycarbonyl group was treated with trifluoroacetic acid as described above in the procedure for synthesizing compound 2388. Compound 2606 (raceme) was obtained as a white solid (0.045 g, yield 74%). MS m / z (ESI+): Calculated mass of compound C22H23BrN8 [M+H]+ = 479.13; Exp = 479.1. High-performance liquid chromatography-2, retention time = 3.75 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97–7.88 (m, 2H), 7.86 (ddd, J = 8.1, 7.2, 1.8 Hz, 1H), 7.56–7.42 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.78–4.56 (m, 2H), 3.91–3.67 (m, 1H), 3.06–2.89 (m, 1H), 2.83–2.70 (m, 1H), 2.44 – 2.25 (m, 2H), 1.91 – 1.71 (m, 1H), 1.65 – 1.51 (m, 1H), 1.49 – 1.28 (m, 2H). The composition of compound 2659 (S mirror isomer) and 2660 (R mirror isomer) 8-Bromo-N2-[(3R)-piperidine-3-yl]-N4-{[4-(pyridine-2-yl)phenyl]methyl}pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine: 2660 (mirror R) and 8-Bromo-N2-[(3R)-piperidine-3-yl]-N4-{[4-(pyridine-2-yl)phenyl]methyl}pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine 2659 (mirror S) were prepared from the optically active tert-butoxycarbonyl amine in the same way with 92% and 86% respectively of the (3R)-3-aminopiperidine-1-carboxylate and (3S)-3-aminopiperidine-1-carboxylate corresponding compounds. 1.10 Composition of compound 2538 The structure of the protected compound is that of the tri-butoxycarbonyl (2S,4R)-tri-butyl 2-(((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)methyl)-4-hydroxypyrrolidine-1-carboxylate It was prepared from (2R,4S)-1-pyrrolidine carboxylic acid 2-(aminomethyl)-4-hydroxy-, 1,1-dimethyl ethyl ester [CAS Reg. No. 1983918-82-6] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.080 g, 0.180 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a white solid (0.086 g, 80% yield). MS m / z (ESI+): Calculated mass of compound C27H31BrN8O3 [M+H]+ = 595.18; Exp = 595.2. High-performance liquid chromatography method 2, retention time = 5.16 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 2H), 7.95 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.86 (td, J = 7.6, 1.8 Hz, 0H), 7.60–7.52 (m, 0.5H, exch NH), 7.47 (d, J = 7.9 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.93–4.62 (m, 3H, exch OH, CH2), 4.29– 3.90 (m, 2H), 3.83 – 3.44 (m, 1H), 3.32 – 3.10 (m, 3H), 1.98 – 1.67 (m, 2H), 1.47 – 1.21 (m, 9H). Composition of compound 2538 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.080 g, 0.134 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2538 was obtained as a gray solid (0.066 g, 98% yield). MS m / z (ESI+): Calculated mass of compound C22H23BrN8O [M+H]+ = 495.13; Exp = 495.1. High-performance liquid chromatography-2, retention time = 3.75 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.95–7.91 (m, 2H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.54–7.42 (m, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.68 (s, 2H), 4.58–4.47 (m, 1H), 4.21–4.02 (m, 1H), 3.51–3.36 (m, 1H), 3.28 – 3.10 (m, 2H), 2.96 – 2.78 (m, 1H), 1.56 (d, J = 56.1 Hz, 4H). 1.11Composition of compound 2571 The structure of the protected compound is tert-butoxycarbonyl(S)-tert-butyl 2-(((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)methyl)pyrrolidine-1-carboxylate It was prepared from (S)-tri-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate [CAS Reg. No. 119020-01-8] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.087 g, 0.196 mmol) described above using the same protocol as for Intermediate IV. The compound protected by the tri-butoxycarbonyl group was obtained as a colorless solid (foam) (0.089 g, yield 78%). HRMS m / z (ESI+): Calculated mass of compound C27H31BrN8O2 [M+H]+ = 579.1826; Exp = 579.1827. High-performance liquid chromatography (HPLC) method 2, retention time = 6.02 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.03 (d, J = 7.9 Hz, 2H), 7.95 (s, 1H), 7.92 (d wide, J = 8.0 Hz, 1H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.94 – 4.61 (m, 2H), 4.02 – 3.78 (m, 1H), 3.32 (s, 4H), 1.94 – 1.56 (m, 4H), 1.45 – 1.22 (m, 9H). Composition of compound 2571 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.087 g, 0.150 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2571 was obtained as a white foam (0.070 g, yield 97%). MS m / z (ESI+): Calculated mass of compound C22H23BrN8 [M+H]+ = 479.1302; Exp = 479.1301. High-performance liquid chromatography-2, retention time = 3.88 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.43 – 8.80 (m, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.95 (s, 1H), 7.93 (dt, J = 8.0, 1.3 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.47 (dt, J = 7.9 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.68 (s, 2H), 3.47 – 2.98 (m (4H), 2.91 – 2.58 (m, 2H), 1.83 – 1.20 (m, 5H). 1.12Composition of compound 2585 The structure of the protected compound is derived from the tert-butoxycarbonyl tert-butyl group (4-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)butyl)carbamate It was prepared from N-(tri-butoxycarbonyl)-1,4-butanediamine [CAS Reg. No. 68076-36-8] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.100 g, 0.226 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tri-butoxycarbonyl group was obtained as a white foam (0.113 g, yield 88%). MS m / z (ESI+): Calculated mass of compound C26H31BrN8O2 [M+H]+ = 567.18; Exp = 567.2. High-performance liquid chromatography (HPLC) 2, retention time = 5.49 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.1 Hz, 2H), 7.97 – 7.91 (m, 2H), 7.90 – 7.83 (m, 1H), 7.55 – 7.41 (m, 2H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.77 – 4.63 (m, 2H), 3.31 – 3.18 (m, 2H), 3.01 – 2.83 (m, 2H), 1.53 – 1.29 (m, 13H). Composition of compound 2585 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.085 g, 0.143 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2585 was obtained as a white foam (0.069 g, yield 98%). MS m / z (ESI+): Calculated mass of compound C21H23BrN8 [M+H]+ = 467.12; Exp = 467.1. High-performance liquid chromatography-2, retention time = 3.56 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.9, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.87 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.54 – 7.42 (m, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.69 (s, 2H), 3.31 – 3.21 (m, 2H), 2.87 – 2.74 (m, 2H); 1.63 – 1.42 (m, 4H). 1.13Composition of compound 2638 The structure of the protected compound is tert-butoxycarbonyl tert-butyl(2-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)ethyl)carbamate It was prepared from 1,1-dimethylethyl N-(2-aminoethyl)carbamate [CAS Reg. No. 57260-73-8] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.074 g, 0.167 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a white solid (foam) (0.075 g, yield 83%). MS m / z (ESI+): Calculated mass of compound C24H27BrN8O2 [M+H]+ = 539.15; Exp = 539.1. High-performance liquid chromatography method 2, retention time = 5.15 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.66 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.1 Hz, 2H), 7.99 – 7.91 (m, 2H), 7.87 (td, J = 7.6, 1.8 Hz, 1H), 7.60 – 7.43 (m, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 6.92 – 6.79 (m, 1H), 4.78 – 4.63 (m, 2H), 3.33 – 3.21 (m, 2H), 3.21 – 3.01 (m, 2H), 1.37 (s, 9H). Composition of compound 2638 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.071 g, 0.132 mmol) as described above in the procedure for synthesizing compound 2388 and purified by silica gel chromatography (1% to 60% methanol / dichloromethane gradient concentration). Compound 2638 was obtained as a white solid (0.041 g, yield 71%). MS m / z (ESI+): Calculated mass of compound C19H19BrN8 [M+H]+ = 439.10; Exp = 439.1. High-performance liquid chromatography method 2, retention time = 3.52 mins. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97 – 7.90 (m, 2H), 7.86 (ddd, J = 8.1, 7.3, 1.8 Hz, 1H), 7.47 (d, J = 8.6 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.68 (s, 2H), 3.32 – 3.20 (m, 2H), 2.75 – 2.56 (m, 2H). 1.14Composition of compound 2586 The structure of the protected compound is tert-butoxycarbonyl tert-butyl(2-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)amino)ethyl)(methyl)carbamate It was prepared from 1,1-dimethylethyl N-(2-aminoethyl)-N-methylcarbamate [CAS Reg. No. 121492-06-6] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.100 g, 0.226 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a white solid (foam) (0.113 g, yield 90%). MS m / z (ESI+): Calculated mass of compound C25H29BrN8O2 [M+H]+ = 553.17; Exp = 553.2. High-performance liquid chromatography method 2, retention time = 5.58 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.68 – 8.63 (m, 1H), 8.04 (d, J = 7.9 Hz, 2H), 7.97 (s, 1H), 7.96 – 7.91 (m, 1H), 7.87 (td, J = 7.7, 1.8 Hz, 1H), 7.53 – 7.43 (m, 3H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.70 (s, 2H), 3.50 – 3.25 (m, 3H), 2.92 – 2.66 (m, 2H), 1.45 – 1.06 (m, 11H). Composition of compound 2586 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.104 g, 0.188 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2586 was obtained as a white solid (0.076 g, yield 89%). MS m / z (ESI+): Calculated mass of compound C20H21BrN8 [M+H]+ = 453.11; Exp = 453.1. High-performance liquid chromatography-2, retention time = 3.52 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.30 – 8.81 (m, 1H), 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.97 – 7.90 (m, 2H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.54 – 7.43 (m, 2H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.69 (s, 2H), 3.39 – 3.33 (m, 2H), 2.71 – 2.55 (m, 2H), 2.38 – 2.15 (m, 3H). 1.15 Compound composition 2600 The structure of the protected compound is tert-butoxycarbonyl tert-butyl(2-((8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)(methyl)amino)ethyl)carbamate It was prepared from 1,1-dimethylethyl N-[2-(methylamino)ethyl]carbamate [CAS Reg. No. 122734-32-1] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.092 g, 0.208 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tri-butoxycarbonyl group was obtained as a white solid (foam) (0.098 g, yield 85%). MS m / z (ESI+): Calculated mass of compound C25H29BrN8O2 [M+H]+ = 553.17; Exp = 553.2. High-performance liquid chromatography method 2, retention time = 6.23 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.14 (t, J = 6.1 Hz, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.03 (d, J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.92 (dt, J = 8.1, 1.3 Hz, 1H), 7.86 (ddd, J = 8.1, 7.2, 1.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 6.93 – 6.69 (m, 1H), 4.69 (d, J = 6.1 Hz, 2H), 3.60 (t, J = 6.4 Hz, 2H), 3.18 – 3.02 (m, 5H), 1.33 (s, 9H). Composition of compound 2600 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.092 g, 0.166 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2600 was obtained as a white foam (0.072 g, yield 95%). MS m / z (ESI+): Calculated mass of compound C20H21BrN8 [M+H]+ = 453.11; Exp = 453.1. High-performance liquid chromatography-2, retention time = 3.99 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.95 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.67 (s, 2H), 3.54 (t, J = 6.7 Hz, 2H), 3.09 (s, 3H) 2.82 – 2.58 (m, 2H). 1.16Composition of compound 2605 It was prepared from sulfoxide III (0.082 g, 0.185 mmol) and N,N'-dimethylaminoethylenediamine as described above for compound 2384. Compound 2605 was obtained as a white foam (0.050 g, yield 58%). MS m / z (ESI+): Calculated mass of compound C21H23BrN8 [M+H]+ = 467.13; Exp = 467.1. High-performance liquid chromatography-2, retention time = 4.09 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ z8.64 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.92 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.1, 7.2, 1.8 Hz, 1H), 7.49 (dwidth, J = 8.0 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.67 (swidth, 2H), 3.63 (t, J = 6.5 Hz, 2H), 3.08 (swidth, (3H), 2.70 – 2.54 (m, 2H), 2.34 – 2.09 (m, 3H). 1.17 Composition of compound 2601 The structure of the protected compound is 4-(8-bromo-4-((4-(pyridine-2-yl)benzyl)amino)pyrazol[1,5-a][1,3,5]triazine-2-yl)piperazine-1-carboxylate. It was prepared from tri-butoxycarbonylpiperazine [CAS Reg. No. 57260-71-6] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (0.091 g, 0.205 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tri-butoxycarbonyl group was obtained as a white solid (foam) (0.098 g, yield 84%). MS m / z (ESI+): Calculated mass of compound C26H29BrN8O2 [M+H]+ = 565.17; Exp = 565.2. High-performance liquid chromatography (HPLC) 2, retention time = 7.08 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.24 (t, J = 6.1 Hz, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 8.00 (s, 1H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.68 (d, J = 5.9 Hz, 2H), 3.76 – 3.69 (m, 4H), 3.42 – 3.32 (m, 4H), 1.40 (s, 9H). Composition of compound 2601 It was prepared by removing the trifluoroacetic acid protective group from the previous tri-butoxycarbonylamino compound (0.092 g, 0.163 mmol) as described above in the procedure for synthesizing compound 2388. Compound 2601 was obtained as a white solid (0.073 g, yield 96%). MS m / z (ESI+): Calculated mass of compound C21H21BrN8 [M+H]+ = 465.12; Exp = 465.1. High-performance liquid chromatography (HPLC) method 2, retention time = 3.99 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.18–9.12 (m, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97 (s, 1H), 7.93 (dt, J = 8.0, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.67 (d, J = 4.9 Hz, 2H), 3.69 – 3.63 (m, 4H), 2.70 – 2.64 (m, 4H). 1.18Composition of compound 2655 The structure of the compound protected by the tert-butoxycarbonyltributyl group is N-[(3S)-1-[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazol[1,5-a][1,3,5]triazine-2-yl]pyrrolidine-3-yl]carbamate It was prepared from tert-butyl N-[(3S)-pyrrolidine-3-yl]carbamate [CAS Reg. No. 122536-76-9] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.069 g, 0.156 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a white solid (foam) (0.088 g, quantified product). MS m / z (ESI+): Calculated mass of compound C26H29BrN8O2 [M+H]+ = 565.17; Exp = 565.3. High-performance liquid chromatography method 2, retention time = 6.00 minutes. Composition of compound 2655 The protected compound was treated with a tri-butoxycarbonyl group (0.086 g, 0.152 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2655 was obtained as a white solid (0.070 g, yield 99%). MS m / z (ESI+): Calculated mass of compound C21H21BrN8 [M+H]+ = 465.11; Exp = 465.2. High-performance liquid chromatography-2, retention time = 3.73 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.2 Hz, 2H), 7.93 (m, 2H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.67 (s, 2H), 3.74 – 3.37 (m, 4H), 3.26 – 3.11 (m, 1H), 2.08 – 1.55 (m, 2H). 1.19 The composition of compounds 2656 (mirror isomer R) and 2657 (mirror isomer S) The structure of the protected compound is that of the tert-butoxycarbonyl tert-butyl (3R)-3-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazol[1,5-a][1,3,5]triazine-yl]amino}pyrrolidine-1-carboxylate It was prepared from tert-butyl(3R)-3-aminopyrrolidine-1-carboxylate [CAS Reg. No. 147081-49-0] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.065 g, 0.147 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a white solid (foam) (0.083 g, quantified product). MS m / z (ESI+): Calculated mass of compound C26H29BrN8O2 [M+H]+ = 565.17; Exp = 565.2. High-performance liquid chromatography method 2, retention time = 6.00 minutes. Composition of compound 2656 The protected compound with a tri-butoxycarbonyl group (0.080 g, 0.141 mmol) was treated with trifluoroacetic acid as described above in the procedure for synthesizing compound 2388. Compound 2656 (the mirror isomer R) was obtained as a white solid (0.051 g, yield 77%). MS m / z (ESI+): Calculated mass of compound C21H21BrN8 [M+H]+ = 465.11; Exp = 465.2. High-performance liquid chromatography-2, retention time = 3.67 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97–7.90 (m, 2H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.52–7.43 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.69 (s, 2H), 4.37–4.19 (m, 1H), 3.00–2.57 (m, 4H), 2.02–1.82 (m, 1H), 1.68 – 1.47 (m, 1H). Composition of compound 2657 Compound 2657 (the mirror isomer S) was prepared as described above for compound 2656 with 79% of the overall yield of tert-butyl(3S)-3-aminopyrrolidine-1-carboxylate [CAS Reg. No. 147081-44-5]. 1.20Composition of compound 2658 The structure of the protected compound from the tert-butoxycarbonyltributyl group is N-(3-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}propyl)carbamate It was prepared from tert-butyl N-(3-aminopropyl)carbamate [CAS Reg. No. 75178-96-0] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.061 g, 0.138 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a white solid (foam) (0.067 g, yield 88%). MS m / z (ESI+): Calculated mass of compound C25H29BrN8O2 [M+H]+ = 553.17; Exp = 553.2. High-performance liquid chromatography method 2, retention time = 6.5.37 minutes. Composition of compound 2658 The protected compound was treated with a tri-butoxycarbonyl group (0.065, 0.149 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2658 was obtained as a white solid (0.053 g, yield 79%). MS m / z (ESI+): Calculated mass of compound C20H21BrN8 [M+H]+ = 453.11; Exp = 453.1. High-performance liquid chromatography-2, retention time = 3.42 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.97 – 7.89 (m, 2H), 7.86 (td, J = 7.6, 1.8 Hz, 1H), 7.52 – 7.42 (m, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.68 (s, 2H), 3.45 – 3.16 (m, 4H), 1.58 (m, 2H). 1.21 Composition of compound 2668 The structure of the tert-butoxycarbonyl tert-butyl group-protected compound is N-[(1S,2S)-2-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}pentylcyclocarbamate It was prepared from tert-butyl N-[(1S,2S)-2-aminopentylcyclocarbamate [CAS Reg. No. 586961-34-4] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.070 g, 0.158 mmol) described above using the same protocol described for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a white solid (foam) (0.079 g, yield 86%). MS m / z (ESI+): Calculated mass of compound C27H31BrN8O2 [M+H]+ = 579.18; Exp = 579.3. High-performance liquid chromatography method 2, retention time = 6.02 minutes. Composition of compound 2668 The compound protected by the tri-butoxycarbonyl group (0.076 g, 0.131 mmol) was treated with trifluoroacetic acid as described above in the procedure for synthesizing compound 2388. Compound 2668 was obtained as a white solid (0.048 g, yield 76%). MS m / z (ESI+): Calculated mass of compound C22H23BrN8 [M+H]+ = 479.13; Exp = 479.1. High-performance liquid chromatography method 2, retention time = 3.75 minutes 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.96 – 7.89 (m, 2H), 7.86 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.55 – 7.38 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.69 (s, 2H), 4.39 (s, 1H), 3.42), 2.15 – 1.12 (m, 6H). 1.22Composition of compound 2669 The structure of the protected compound is that of tert-butoxycarbonyl tert-butyl N-[(1S,3S)-3-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}pentylcyclocarbamate It was prepared from tert-butyl N-[(1S,3S)-3-aminopentylcyclocarbamate [CAS Reg. No. 645400-44-8] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.071 g, 0.160 mmol) described above using the same protocol described for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a white solid (foam) (0.075 g, yield 81%). MS m / z (ESI+): Calculated mass of compound C27H31BrN8O2 [M+H]+ = 579.18; Exp = 579.3. High-performance liquid chromatography method 2, retention time = 5.70 minutes. Composition of compound 2669 The protected compound with a tri-butoxycarbonyl group (0.0715 g, 0.123 mmol) was treated with trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2669 was obtained as a white solid (0.045 g, yield 79%). MS m / z (ESI+): Calculated mass of compound C22H23BrN8 [M+H]+ = 479.13; Exp = 479.2. High-performance liquid chromatography-2, retention time = 3.61 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.96 – 7.89 (m, 2H), 7.86 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.55 – 7.38 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.69 (s, 2H), 4.39 (s, 1H), 3.42 – 3.31 (m, 1H), 2.15 – 1.12 (m, 6H). 1.23 Composition of compound 2670 The structure of the protected compound is tert-butoxycarbonyl tert-butyl N-[(1S,3R)-3-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazol[1,5-a][1,3,5]triazine-2-yl]amino}hexylcyclocarbamate It was prepared from tert-butyl N-[(1S,3R)-3-aminohexylcyclocarbamate [CAS Reg. No. 1298101-47-9] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.068 g, 0.153 mmol) described above using the same protocol described for intermediate compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a white solid (foam) (0.080 g, yield 88%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.3. High-performance liquid chromatography method 2, retention time = 5.92 minutes. Composition of compound 2670 The protected compound was treated with a tri-butoxycarbonyl group (0.0765 g, 0.129 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2670 was obtained as a white solid (0.038 g, yield 60%). MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.2. High-performance liquid chromatography-2, retention time = 3.81 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (dt, J = 4.5, 1.5 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.96 – 7.89 (m, 2H), 7.88 – 7.80 (m, 1H), 7.53 – 7.43 (m, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.76 – 4.57 (m, 2H), 3.87 – 3.60 (m, 1H), 2.69 – 2.55 (m, 1H), 2.02 – 1.56 (m, 4H), 1.35 – 0.78 (m, 4H). 1.24 Composition of compound 2671 The structure of the intermediate compound protected by the tert-butoxycarbonyl tert-butyl group is N-[(1S,2S)-2-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}hexylcyclo]carbamate It was prepared from tert-butyl N-[(1S,2S)-2-aminohexylcyclocarbamate [CAS Reg. No. 180683-64-1] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.071 g, 0.160 mmol) described above using the same protocol described for intermediate compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a white solid (foam) (0.091 g, yield 96%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.3. High-performance liquid chromatography method 2, retention time = 6.22 minutes. Composition of compound 2671 The compound protected by the tri-butoxycarbonyl group (0.089 g, 0.150 mmol) was treated with trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2671 was obtained as a white solid (0.064 g, yield 86%). MS m / z (ESI+): Calculated mass of compound C23H25BrN8 [M+H]+ = 493.15; Exp = 493.2. High-performance liquid chromatography (HPLC) method 2, retention time = 4.17 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.04 (ddd, J = 8.0 Hz, 2H), 7.98 – 7.90 (m, 2H), 7.89 – 7.82 (m, 1H), 7.52 – 7.46 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.82 – 4.51 (m, 2H), 3.68 – 3.34 (m, 2H), 2.69 – 2.31 (m, 1H), 2.02 – 1.50 (m, 2H), 1.34 – 0.93 (m, 5H). 1.25 Compound composition 2672 The structure of the protected compound is N-[(1S,2R)-2-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazol[1,5-a][1,3,5]triazine-2-yl]amino}hexylcyclocarbamate It was prepared from tert-butyl N-[(1S,2R)-2-aminohexylcyclocarbamate [CAS Reg. No. 365996-30-1] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.070 g, 0.158 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a white solid (foam) (0.091 g, 97% yield). MS m / z (ESI+): Calculated mass of compound C28H33BrN8O2 [M+H]+ = 593.20; Exp = 593.3. High-performance liquid chromatography method 2, retention time = 6.08 minutes. Composition of compound 2672 The protected compound was treated with a tri-butoxycarbonyl group (0.088 g, 0.148 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2672 was obtained as a white solid (0.064 g, yield 73%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8 [M+H]+ = 493.15; Exp = 493.2. High-performance liquid chromatography-2, retention time = 4.21 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.99 (s, 1H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.72 (m, 2H), 4.17 – 3.93 (m, 1H), 1.83 – 1.22 (m, 9H). 1.26Composition of compound 2636 The structure of the protected compound is tert-butoxycarbonyl tert-butyl N-{[coupled 4-{[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}hexylcyclo]methyl}carbamate It was prepared from tert-butyl N-[(cross-4-aminohexylcyclo)methyl]carbamate [CAS Reg. No. 192323-07-2] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.080 g, 0.18 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by a tert-butoxycarbonyl group was obtained as a white solid (foam) (0.083 g, yield 76%). MS m / z (ESI+): Calculated mass of compound C29H35BrN8O2 [M+H]+ = 607.21; Exp = 607.2. High-performance liquid chromatography method 2, retention time = 5.96 minutes. Composition of compound 2636 The protected compound was treated with a tri-butoxycarbonyl group (0.081 g, 0.133 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound 2636 was obtained as a white solid (0.041 g, yield 61%). MS m / z (ESI+): Calculated mass of compound C24H27BrN8 [M+H]+ = 507.16; Exp = 507.2. High-performance liquid chromatography-2, retention time = 3.81 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.62 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.01 (d, J = 7.9 Hz, 2H), 7.94 – 7.89 (m, 2H), 7.85 (ddd, J = 8.0, 7.1, 1.8 Hz, 1H), 7.52 – 7.41 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.74 – 4.56 (m, 2H), 3.77 – 3.56 (m, 1H), 2.36 (d, J = 6.3 Hz, 2H), 1.97 – 1.64 (m, (4H), 1.32 – 0.80 (m, 5H). 1.27 Composition of compound 2635 The structure of the protected compound is tert-butoxycarbonyl tert-butyl N-[bromo-4-({[8-bromo-4-({[4-(pyridine-2-yl)phenyl]methyl}amino)pyrazolo[1,5-a][1,3,5]triazine-2-yl]amino}methyl)hexylcyclocarbamate It was prepared from tert-butyl N-[separated-4-(aminomethyl)hexylcyclo]carbamate [CAS Reg. No. 177583-27-6] and the sulfoxide 8-bromo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (0.081 g, 0.183 mmol) described above using the same protocol as for intermediate compound IV. The compound protected by the tert-butoxycarbonyl group was obtained as a white solid (foam) (0.085 g, yield 77%). MS m / z (ESI+): Calculated mass of compound C29H35BrN8O2 [M+H]+ = 607.21; Exp = 607.2. High-performance liquid chromatography method 2, retention time = 5.97 minutes. Composition of compound 2635 The protected compound was treated with a tri-butoxycarbonyl group (0.0825 g, 0.136 mmol) using trifluoroacetic acid as described above in the procedure for the synthesis of compound 2388. Compound D27 was obtained as a white solid (0.020 g, yield 29%). MS m / z (ESI+): Calculated mass of compound C28H33BrN8 [M+H]+ = 507.16; Exp = 507.2. High-performance liquid chromatography-2, retention time = 3.75 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.66 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.97 – 7.91 (m, 2H), 7.87 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.52 – 7.42 (m, 2H), 7.37 – 7.31 (m, 1H), 4.69 (d, J = 7.2 Hz, 2H), 3.16 – 3.01 (m, 2H), 1.83 – 0.67 (m, 10H). 1.28 Compound composition 2590 The iodine derivative 2590 was prepared as described above in the synthesis of compounds 2384 and 2388. Composition of compound V Compound V (8-iodo-2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 147916-85-6]) was prepared by the standard iodine addition protocol for compound 2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 54346-18-8], as described above for the compound derived from iodine I (N-iodosuccinimide was used instead of N-bromosuccinimide). Composition of compound VI It was prepared from 8-iodo-2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 147916-85-6] (compound V) (0.200 g, 0.649 mmol) as described above for compound II. Compound VI (0.196 g, 64% yield) was obtained as a white powder. MS m / z (ESI+): Calculated mass of compound C18H15IN6S[M+H]+ = 475.02; Exp = 475.0. High-performance liquid chromatography-2, retention time = 6.08 mins. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.61 (t, J = 6.3 Hz, 1H), 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.18 (s, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.93 (dt, J = 8.0, 1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.8 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.74 (d, J = 6.2 Hz, 2H), 2.5 (s, 3H) (Below the solvent peak). Composition of compound VII Compound III was prepared as described above by oxidation of the preceding compound 8-iodo-2-(methylthio)-N-(4-(pyridine-2-yl)benzyl)pyrazol[1,5-a][1,3,5]triazine-4-amine (compound VI) (0.193 g, 0.407 mmol). Compound VII (0.199 g, quantified product) was obtained as a white powder. MS m / z (ESI+): Calculated mass of compound C18H15IN6OS[M+H]+ = 491.01; Exp = 491.0. High-performance liquid chromatography (HPLC) 2, retention time = 4.00 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 10.04 (s, 1H), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.37 (s, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.79 (s, 2H), 2.83 (s, 3H). Compound VIII It was prepared from N-tert-butoxycarbonyl-trans-1,4-chlorohexanediamide [CAS Reg. No. 195314-59-1] and the sulfoxide 8-iodo-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (compound VII) (0.065 g, 0.133 mmol) described above using the same protocol as previously described for intermediate compound IV. Compound VIII was obtained as a white solid (0.054 g, yield 64%). MS m / z (ESI+): Calculated mass of compound C28H33IN8O2 [M+H]+ = 641.18; Exp = 641.2. High-performance liquid chromatography (HPLC) method 2, retention time = 5.93 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.16, 8.87 (2 s, 1H, exch NH), 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 7.9 Hz, 2H), 7.95–7.81 (m, 3H), 7.52–7.41 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 7.25 (d, J = 7.8 Hz, 0.5 H, exch NH), 7.08 (d, J = 8.1 Hz, 0.5 H) exch NH), 6.73 (s, 1H), 4.74 – 4.55 (m, 2H), 3.76 – 3.52 (m, 1H), 3.25 – 3.06 (m, 1H), 1.76 (s, 4H), 1.38 (s, 9H), 1.35 – 1.10 (m, 4H). Composition of compound 2590 It was prepared by removing the trifluoroacetic acid protection of the former tri-butoxycarbonylamino VIII compound (0.051 g, 0.080 mmol) as described above for compound 2388. Compound 2590 was obtained as a gray solid (0.028 g, yield 65%). MS m / z (ESI+): Calculated mass of compound C23H25IN8 [M+H]+ = 541.13; Exp = 541.1. High-performance liquid chromatography (HPLC) method 2, retention time = 3.77 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.03 (d, J = 8.2 Hz, 2H), 7.95–7.89 (m, 1H), 7.89–7.82 (m, 2H), 7.54–7.42 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 7.23 (d, J = 7.9 Hz, 0.5H exch NH), 7.04 (d, J = 8.2 Hz, 0.5H exch NH), 4.74– 4.58 (m, 2H), 3.78 – 3.55 (m, 1H), 2.50 – 2.40 (m, 1H), 1.92 – 1.03 (m, 8H). 1.29Composition of compound 2629 Chlorine derivative 2629 was prepared as described above in the synthesis of compounds 2384 and 2388. The structure of compound IX Compound IX (8-chloro-2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 1843260-73-0]) was prepared by the standard chlorination protocol for compound 2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 54346-18-8] using N-chlorosuccinate imide instead of N-bromosuccinate imide. Composition of compound X It was prepared from 8-chloro-2-(methylthio)pyrazolo[1,5-a]-1,3,5-triazine-4(3H)-one [CAS Reg. No. 1843260-73-0] (compound IX) (0.250 g, 1.154 mmol) as described above for compound II. Compound X (0.407 g, 92% yield) was obtained as a beige powder. MS m / z (ESI+): Calculated mass of compound C18H15ClN6S[M+H]+ = 383.08; Exp = 383.1. High-performance liquid chromatography-2, retention time = 5.68 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.68 (t, J = 6.3 Hz, 1H), 8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.26 (s, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.94 (dt, J = 8.0, 1.2 Hz, 1H), 7.87 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.34 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.74 (d, J = 6.3 Hz, 2H), 2.49 (s, 3H). Composition of compound XI Compound II was prepared as described above by oxidation of the preceding compound 8-chloro-2-(methylthio)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (compound X) (0.353 g, 0.922 mmol). Compound XI (quantitative product) was obtained as a white powder. MS m / z (ESI+): Calculated mass of compound C18H15ClN6OS[M+H]+ = 399.08; Exp = 399.1. High-performance liquid chromatography (HPLC) 2, retention time = 3.79 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 10.11 (s, 1H), 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.35 (s, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.96 – 7.91 (m, 1H), 7.86 (ddd, J = 8.0, 7.3, 1.8 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.33 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.77 (s, 2H), 2.82 (s, 3H). Composition of compound XII It was prepared from N-tert-butoxycarbonyl-trans-1,4-chlorohexanediamide [CAS Reg. No. 195314-59-1] and the sulfoxide 8-chloro-2-(methylsulfenyl)-N-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-4-amine (compound XI) (0.100 g, 0.251 mmol) described above using the same protocol as described above for intermediate compound IV. Compound XII was obtained as a white solid (0.107 g, yield 78%). MS m / z (ESI+): Calculated mass of compound C28H33ClN8O2 [M+H]+ = 549.25; Exp = 549.2. High-performance liquid chromatography method 2, retention time = 5.76 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.66 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.09 – 8.02 (m, 2H), 7.98 – 7.91 (m, 2H), 7.87 (td, J = 7.6, 1.8 Hz, 1H), 7.54 – 7.42 (m, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 6.81 – 6.70 (m, 1H), 4.77 – 4.58 (m, 2H), 3.77 – 3.52 (m, 1H), 3.25 – 3.07 (m, 1H), 1.96 – 1.64 (m, 4H), 1.39 (s, 9H), 1.35 – 1.07 (m, 4H). Composition of compound 2629 It was prepared by removing the trifluoroacetic acid protective group from the former tri-butoxycarbonylamino compound XII (0.103 g, 0.188 mmol) as described for compound IV. Compound 2629 was obtained as a gray solid (0.082 g, yield 97%). MS m / z (ESI+): Calculated mass of compound C20H21BrN8 [M+H]+ = 449.20; Exp = 449.2. High-performance liquid chromatography-2, retention time = 3.59 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.2 Hz, 2H), 7.96 – 7.90 (m, 2H), 7.86 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.54 – 7.43 (m, 2H), 7.33 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 4.71 – 4.61 (m, 2H), 3.78 – 3.54 (m, 1H), 2.50 – 2.38 (m, 1H), 1.93 – 0.99 (m, 8H). 1.30 Compound composition 2420 Compound 2420 [CAS Reg. No. 2254007-13-9], N2-((1r,4r)-4-aminohexylcyclo)-8-isopropyl-N4-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine, was obtained as described in G. Compain et al, Eur. J. Med. Chem, 2018, 208, 158, 1-6 (doi.org / 10.1016 / j.ejmech.2018.08.100). 1.31 Composition of compound 2428 Composition of compound XIII It was prepared from tert-butyl 4-aminopiperidine-1-carboxylate [CAS 87120-72-7] and the sulfoxide compound 8-(1-methylethyl)-2-(methylsulfenyl)-N-[[4-(2-pyridinyl)phenyl]methyl]pyrazolo[1,5-a]-1,3,5-triazine-4-amine known [CAS Reg. No. 1244955-43-8]; see G. Compain et al, Eur. J. Med. Chem, 2018, 208, 158, 1-6 (0.074 g, 0.136 mmol) using the same protocol described above for intermediate compound IV. Compound XIII was obtained as a white solid. High-performance liquid chromatography method 2, retention time = 5.96 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.35 – 8.28 (m, 1H), 7.78 (d, J = 7.9 Hz, 2H), 7.73 (s, 1H), 7.64 – 7.54 (m, 1H), 7.49 – 7.42 (m, 2H), 7.41 – 7.36 (m, 2H), 4.67 (s, 2H), 4.00 – 3.71 (m, 3H), 3.04 – 2.69 (m, 3H), 1.96 – 1.55 (m, 2H), 1.50 – 1.11 (m, 17H). Composition of compound 2428 It was prepared by removing the trifluoroacetic acid protective group from the former tri-butoxycarbonylamino XIII, as a white solid. MS m / z (ESI+): Calculated mass of compound C25H30N8 [M+H]+ = 443.27; Exp = 443.3. High-performance liquid chromatography (HPLC) method 2, retention time = 4.08 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.04 (d, J = 8.0 Hz, 2H), 7.93 (dt, J = 8.1, 1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.8 Hz, 1H), 7.71 (s, 1H), 7.47 (d, J = 7.9 Hz, 2H), 7.34 (ddd, J = 7.2, 4.8, 1.4 Hz, 1H), 4.66 (s wide, 2H), 3.78 – 3.60 (m, 1H), 2.99 – 2.81 (m, 3H), 2.50 – 2.41 (m, 2H), 1.92 – 1.59 (m, 2H), 1.41 – 1.10 (m, 8H). 1.32 Composition of compound 2478 It was prepared from the known 2-(methylthio)-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbontrile (see G. Compain et al, Eur. J. Med. Chem, 2018, 208, 158, 1-6 [CAS n°1273577-70-0]). Composition of compound XIV It was prepared from 2-(methylthio)-4-oxo-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-carbonitrile [CAS Reg. No. 1273577-70-0] (compound XIV) (0.195 g, 0.941 mmol) as described above for compound II. Compound XV (0.308 g, 88% yield) was obtained as a foam. MS m / z (ESI+): Calculated mass of compound C19H15N7S [M+H]+ = 374.12; Exp = 374.1. High-performance liquid chromatography-2, retention time = 5.00 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 9.93 (t, J = 6.0 Hz, 1H), 8.65 (d, J = 4.0 Hz, 1H), 8.60 (s, 1H), 8.05 (d, J = 7.9 Hz, 2H), 7.94 (d, J = 7.6 Hz, 1H), 7.87 (t, J = 7.7 Hz, 1H), 7.49 (s, 2H), 7.39 – 7.30 (m, 1H), 4.76 (d, J = 6.1 Hz, 2H), 2.50 (CH3S under solvent signal, 3H). Composition of compound XVI Compound III was prepared as described above by oxidation of the preceding compound, methylsulfonyl XV (0.300 g, 0.803 mmol). Compound XI (quantitative product) was obtained as a white foam. MS m / z (ESI+): Calculated mass of compound C19H15N7OS [M+H]+ = 390.11; Exp = 390.1. High-performance liquid chromatography (HPLC) 2, retention time = 3.39 min. Composition of compound 2478 It was prepared from the previous sulfoxide compound XVI (0.101 g, 0.259 mmol) as described above for compound 2384. Compound 2478 was obtained as a foam (0.059 g, yield 52%). MS m / z (ESI+): Calculated mass of compound C24H25N9 [M+H]+ = 440.23; Exp = 440.2. High-performance liquid chromatography-2, retention time = 3.63 mins. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.65 (d, J = 4.2 Hz, 1H), 8.29 (d, J = 6.4 Hz, 1H), 8.04 (d, J = 7.7 Hz, 2H), 7.96 – 7.83 (m, 2H), 7.53 – 7.43 (m, 2H), 7.36 – 7.30 (m, 1H), 4.71 – 4.61 (m, 2H), 3.81 – 3.53 (m, 1H), 2.50 under solvent peak (m, 1H), 1.88 – 1.64 (m, 4H), 1.36 – 0.99 (m, 4H). 1.33Composition of compound 2533 Compound 2384 was prepared following the procedures described above, using 4-morpholine-4-ylmethylphenylamine (CAS Reg. No. 51013-67-3) instead of 4-(pyridine-2-yl)phenyl)methamine. Compound 2533 was obtained as a white foam (0.056 g, yield 93%). MS m / z (ESI+): Calculated mass of compound C22H29BrN8O [M+H]+ = 501.17; Exp = 501.2. High-performance liquid chromatography-2, retention time = 3.75 min. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.01 (s, 1H), 7.87 – 7.76 (m, 2H), 7.32 – 7.23 (m, 2H), 3.57 (t, J = 4.6 Hz, 5H), 3.45 (m, 2H), 3.37 – 3.29 (m, 1H), 2.40 – 2.30 (m, 4H), 1.95 – 1.71 (m, 4H), 1.40 – 1.01 (m, 4H). 1.34Composition of compound 2554 Compound 2388 was prepared following the procedures described above, using 4-morpholine-4-ylmethylphenylamine (CAS Reg. No. 51013-67-3) instead of 4-(pyridine-2-yl)phenyl)methamine. Compound 2554 was obtained as a beige solid. MS m / z (ESI+): Calculated mass of compound C21H27BrN8O [M+H]+ = 487.16; Exp = 487.1. High-performance liquid chromatography-2, retention time = 3.77 minutes. 1H NMR (300 MHz, dimethyl sulfoxide) δ 8.02 (s, 1H), 7.87 – 7.78 (m, 2H), 7.32 – 7.24 (m, 2H), 3.91 – 3.60 (m, 1H), 3.59 – 3.54 (m, 4H), 3.48 – 3.42 (m, 2H), 3.01 – 2.91 (m, 2H), 2.39 – 2.30 (m, 4H), 1.86 – 1.76 (m, 2H), 1.45 – 1.11 (m, 4H). 1.35 Composition of the compound PL_00029 Composition of compound XVIII A mixture of 4-fluoro-2H-pyrazol-3-amine (1.9 g, 18.797 mmol) in ethyl acetate (50 mL) was cooled at 0 °C in ice water, and then ethyl[(thiooxomethylidine)amino]methanoate (2.217 mL, 18.797 mmol) was added in N₂ medium. After the addition, the resulting solution was heated at 80 °C for 4 hours until liquid chromatography by mass spectrometry showed the reaction was complete. The mixture was then concentrated, and the residue was washed with Et₂O (10 mL) to obtain compound XVIII (3.33 g, 76% yield) as a white solid. ESI m / z 233.0 (M + H)⁺. Composition of compound XIX A mixture of compound XVIII (3.33 g, 14.339 mmol) and 2CO3 (3.96 g, 28.678 mmol) was stirred in acetonitrile (100 mL) at 80 °C for 12 hours. Liquid chromatography by mass spectrometry confirmed that the reaction was complete. The mixture was filtered and concentrated to obtain the filtrate. The residue was dissolved in H2O (40 mL) and the mixture was acidified to pH 7 using acetic acid (1 mL). The precipitate was collected by filtration to obtain compound XIX (2.1 g, 78% yield) as a yellow solid. ESI m / z 186.9 (M + H)+, 208.9 (M + Na)+. Composition of compound XX To a mixture of compound XIX (2.1 g, 11.281 mmol) and NaOH (1.35 g, 33.842 mmol) in ethanol (30 mL) and H₂O (15 mL), CH₃I (0.702 mL, 11.281 mmol) was added at room temperature. After the addition, the mixture was stirred for 2 hours, and liquid chromatography-mass spectrometry showed that the reaction was complete. The mixture was concentrated and acidified to pH 6 using neutral aqueous HCl (17 mL). The solid was collected by filtration to obtain compound XX (1.03 g, yield 45%) as a yellow solid. ESI m / z 201.1 (M + H)⁺, 423.0 (2M + Na)⁺. Composition of compound XXI To a mixture of compound XX (1.03 g, 5.145 mmol) in POCl3 (10 mL), diisopropyl ethylamine (2.551 mL, 15.435 mmol) was added. After the addition, the mixture was stirred at 90 °C for 2 hours, and liquid chromatography-mass spectrometry showed that the reaction was complete. The mixture was concentrated and dried under vacuum to obtain crude compound XXI (5, 1.09 g, 96%) as a yellow solid. The crude product was used directly for the next step without purification. ESI m / z 219 (M + H)+. The structure of compound XXII A mixture of compound XXI (1.09 g, 4.986 mmol), [4-(pyridine-2-yl)phenyl]methamine (0.92 g, 4.986 mmol), and diisopropylethylamine (4.120 mL, 24.928 mmol) was stirred in acetonitrile (20 mL) at room temperature for 12 hours. Liquid chromatography by mass spectrometry showed that the reaction was complete. The mixture was filtered and concentrated. The residue was washed with H₂O (40 mL) and filtered to obtain compound XXII (1 g, 55% yield) as a yellow solid. ESI m / z 367 (M + H)⁺. Composition of compound XXIII To a mixture of compound XXII (550 mg, 1.501 mmol) in dichloromethane (40 mL), MCPBA (1.388 mL, 4.503 mmol) was added at room temperature. After addition, the mixture was stirred for 3 hours, and liquid chromatography by mass spectrometry showed that the reaction was complete. The mixture was diluted with dichloromethane (100 mL) and washed with a 10% aqueous solution of Na₂SO₃ (40 mL x 3 mL). The organic layer was incorporated and dried with Na₂SO₄. The mixture was filtered, the filtrate concentrated, and then purified by reverse-phase column chromatography (C18 column, with sequential filtration using 0–80% acetonitrile in H₂O with 0.05% trifluoroacetic acid) to give compound XXIII (400 mg, yield 66%) as a yellow solid. ESI m / z 399 (M + H)+. Composition of compound XXIV A mixture of XXIII (400 mg, 1.004 mmol) and 2-methylpropane-2-yl{[(1r,4r)-4-aminohexylcycloamino}methanoate (430.32 mg, 2.008 mmol) in 1-methyl-2-pyrrolidinone (2.5 mL) was microwaved at 150 °C for 1.5 hours, and liquid chromatography by mass spectrometry showed that the reaction was complete. The mixture was then purified by reverse-phase column chromatography (C18 column, with sequential filtration using 0–95% acetonitrile in H₂O with 10 mM NH₄HCO₃) to give compound XXIV (213 mg, 39% yield) as a yellow solid. ESI m / z 533.4 (M + H)⁺. Installation of PL_00029 A mixture of compound XXIV (213 mg, 0.400 mmol) in dichloromethane (2 mL) was treated with trifluoroacetic acid (1 mL, 13.463 mmol) and stirred at room temperature for 2 hours until liquid chromatography-mass spectrometry showed the reaction was complete. The mixture was concentrated and the residue purified by preparative high-performance liquid chromatography (CPLC) (C18 column, using 0–95% acetonitrile in H₂O with 10 mM NH₄HCO₃) to give compound PL_00029 (29.4 mg, 17%) as a white solid. ESI m / z 433 (M + H)+.1H NMR (400 MHz, dimethyl sulfoxide-d6)δ 8.65-8.64 (dd, J = 4.8 Hz, 0.8 Hz, 1H), 8.05 (d, J = 8.0 Hz, 2H), 7.94(s, 1H), 7.92 (d, J = 13.2 Hz, 1H), 7.88-7.84 (m, 1H), 7.51-7.45 (m, 2H), 7.535-7.32 (m, 1H), 7.02-7.00 (m, 1H), 4.68-4.63 (m, 2H), 3.65-3.63 (m, 1H), 3.35-3.16 (m, 1H), 1.86-1.73 (m, 4H), 1.30-1.08 (m, 4H) ppm. No signals from three NH protons were detected. Example 2: General cell culture practices and animal experiments The human cancer cell lines used in the current project were purchased from either the American Type Culture Collection (ATCC), the German Microbiology and Cell Cultures Group, Ltd. (DSMZ), or the European Consortium of Approved Cell Houses (ECACC). For experimental use, cells were cultured according to established good cell culture practices, following the instructions of the original supplier of the ATCC / DSMZ / ECACC collections regarding cell culture media and supplements, cryopreservation, and subculture procedures. Cells were incubated in 5% CO2-enriched medium at 37°C for no more than two months. The animal procedures were carried out in accordance with EU Directive 86 / 609 / EEC. The experiments were conducted under individual authorization and in approved animal care facilities. Example 3: In vitro cytotoxicity assay of the 2,8-halogen-N4-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine substituent family of compounds The in vitro cytotoxicity of the detection compounds was evaluated in several human cancer cell lines. Cells were seeded in 96-cavity plates at appropriate densities depending on the cell line (between 1,000 and 10,000 cells / cavity in 100 μL of suitable culture medium) and incubated at 37°C for 24 hours. Serial dilutions of the tested compound, pre-dissolved in the culture medium (50 μL), were added, and incubation was carried out at 37°C for 5–9 days. MTT (5 mg / mL in phosphate-buffered saline, 20 μL, Sigma-Aldrich) was added to the cavities, and incubation continued for 1–4 hours at 37°C. The culture medium was then carefully removed, and the cavity contents were homogenized using acidic isopropanol. Absorption values ​​were measured on a microplate reader using a wavelength of 570 nm (with a reference wavelength of 690 nm). Alternatively, cell viability was determined using the cell-titer glo® reagent (Promega).IC50 concentration values ​​were determined compared to untreated control cells using an inhibitory dose-response curve fitting (GraphPad Prism 9). Exatecan mesylate (catalog number HY-13631A) and CR8 (CAS registration number 294646-77-8; catalog number HY-18340) were purchased from MedChemExpress (China). Table 1 below shows the IC50 values ​​of cytotoxicity observed in vitro for the detection compounds in a range of human cancer cell lines. Low nanomolar activity was observed with the invention compounds. Compared to CR8, a known molecular glue degrader of CycK (see: Słabicki, M., Kozicka, Z., Petzold, G. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293–297, 2020), the invention compounds were 2–100 times more potent. Table 1: Summary of IC50 values ​​for in vitro cytotoxicity of detection compounds (in nanomolars) cell line Compound BT-474 NCI-N87 MDA-MB-453 SKBR-3 MDA-MB-231 JIMT-1 MCF-7 HT-29 BXPC3 OE-19 A549 KB-1 HCT-116 Caco-2 2384 0.94 0.76 0.53 0.73 0.38 0.25 3.42 0.22 1.46 2.24 0.56 0.38 1.19 6.64 2388 1.64 1.40 1.27 1.68 0.76 0.64 5.40 0.23 1.97 3.77 0.65 1.66 4.46 2420 3.41 4.93 2.73 3.25 0.70 0.61 7.78 1.74 6.91 1.99 4.40 56.15 2428 3.73 4.50 3.11 1.94 2.31 0.92 9.12 0.83 7.84 2.22 5.31 24.20 2478 1.72 6.88 1.34 17.59 1.64 1.18 2533 >100 >100 >100 >100 >100 >100 2538 6.54 21.59 8.12 39.15 8.75 5.13 2554 >100 >100 >100 >100 >100 >100 2559 2.63 1.32 1.52 3.73 1.35 0.41 12.85 0.21 1.63 2560 5.92 3.29 1.61 4.33 1.92 0.60 2568 1.75 2.22 1.67 4.36 0.98 0.62 11.57 0.46 4.86 4.95 2569 15.22 19.70 12.81 62.61 11.24 6.70 2571 2.68 4.27 3.55 7.75 2.22 1.53 79.63 1.12 5.43 2584 9.72 9.44 12.33 25.91 7.17 7.61 2585 1.77 15.41 26.75 38.89 24.72 7.86 2586 1.73 3.14 2.47 6.59 1.44 1.13 33.90 0.45 2.44 2590 1.33 2.42 1.76 2.55 0.74 0.29 2600 1.18 1.32 1.17 1.69 0.29 0.19 12.19 0.28 1.16 1.48 2601 1.86 2.70 1.92 3.61 0.86 0.45 15.36 0.13 1.72 2605 2.76 4.50 3.66 7.46 1.54 1.22 3.70 0.33 2.91 2606 0.92 0.77 0.64 1.23 0.46 0.88 6.88 0.13 1.16 2622 13.47 3.00 21.14 2.24 12.72 4.84 >100 8.25 36.13 2629 1.75 0.94 0.77 0.27 0.66 0.11 3.91 0.36 1.17 2635 23.12 15.88 17.94 0.83 12.87 3.52 >100 8.93 39.70 2636 3.68 2.46 1.97 0.17 1.46 0.12 33.12 1.28 4.68 8.10 2659 0.72 0.34 0.40 0.72 0.26 2660 1.25 0.49 0.68 0.11 0.43 2638 0.78 0.42 0.88 0.82 0.30 2658 4.57 6.43 7.84 0.77 1.98 2655 1.57 1.95 0.97 0.14 0.54 1.66 2656 2.52 1.42 1.13 0.17 0.65 2657 1.71 0.43 0.77 0.13 0.56 2668 2.16 0.84 1.78 0.20 0.82 2.99 2669 1.75 0.39 0.59 0.67 0.44 2670 5.77 2.53 9.19 0.72 2.67 2671 3.34 1.47 2.22 0.42 1.74 7.60 2672 2.12 0.55 0.76 0.24 0.46 CR8* 18.4 62.2 40.3 30.6 10.4 25.2 *CR8 is a known molecular glue degrader of CycK (see: Słabicki, M., Kozicka, Z., Petzold, G. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293–297, 2020), but with limited efficacy (IC50 activity range is high in nanomolars). Figures 1-9 and 10-14 show a side-by-side comparison between the halogen-treated compound 2384 and its isopropyl analog 2420. The halogen-treated compound 2384 is systematically more effective than its isopropyl analog. This indicates that the insertion of a halogen atom at this position increases the compound's effectiveness. Figures 15-23 and 24-28 show a side-by-side comparison between the halogen-treated compound 2388 and its isopropyl analog 2428. The halogen-treated compound 2384 is systematically more active than its isopropyl analog. This indicates that the introduction of a halogen atom at this position increases the compound's activity. Figure 29-33 shows a side-by-side comparison between compound 2384, as reported, and compound CR8, a known molecular glue degrader of CycK (see: Słabicki, M., Kozicka, Z., Petzold, G. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585, 293–297, 2020). Halogen-treated compound 2384 shows a significant improvement in activity at low nanomolar levels, while compound CR8 exhibits activity in the high nanomolar range. This example demonstrates that the series of halogenated compounds in the invention is more effective than its isopropyl counterpart and the well-known molecular glue solvent CR8. Example 4: Evaluation of in vivo mouse tolerance to the 2,8-halogen-N4-(4-(pyridine-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine substituent family of compounds Tolerance tests were conducted in mice using selected compounds from this discovery. Female CD-1 mice (number = 5 mice per group) were treated with a single intravenous dose of the compound at a concentration of 1 mg / kg. The carrier was a phosphate-buffered saline solution with a pH of 6.0. The mice were carefully monitored for mortality, external clinical findings, weight loss, behavior, and the appearance of overt signs of toxicity over a period of 21 days. Table 2 below shows the average weight change over time and animal mortality for each compound. Some of the identified compounds were relatively better tolerated than others, which may support an improved therapeutic index. Table 2. Average weight change (percentage of initial weight) over time and animal mortality in the in vivo mouse endurance study The compound on study day 1 2 3 4 5 6 7 8 9 10 2384 Average 0.0 -2.5 -7.1 -14.6 -15.2 -14.9 -12.4 -9.2 -7.3 -1.9 Tight Closing Direction (SD) 0.0 2.3 6.3 9.2 9.4 11.8 13.1 11.5 11.2 12.6 Number of participants: 5555555555555 2388 Average 0.0 -7.1 -15.5 -21.9 -29.7 -33.8 Tightness (SD) direction 0.0 2.5 3.8 6.7 5.2 4.0 Number of participants: 55555333 2559 Average 0.0 -11.4 -20.2 -29.0 -33.9 -36.9 -39.4 Tightness (SD) direction of closure 0.0 0.8 0.9 1.8 4.6 3.9 0.2 Number of participants: 55555442 2560 Average 0.0 -2.1 1.4 3.2 4.2 4.4 4.1 6.7 7.9 8.3 Tight Closing Direction (SD) 0.0 3.1 2.6 1.6 2.3 2.1 1.5 1.8 2.4 4.2 Number of participants: 5555555555555 2568 Average 0.0 0.7 -0.2 1.9 2.9 2.4 2.7 4.8 6.9 5.1 Tight Closing Direction (SD) 0.0 1.2 4.3 3.7 3.5 3.3 3.0 3.0 4.4 3.4 Number of participants: 5555555555555 2571 Average 0.0 1.7 1.6 2.4 4.5 3.8 3.0 5.9 9.1 9.1 Tight Closing Direction (SD) 0.0 2.6 3.2 3.5 2.4 1.9 3.0 4.8 3.1 3.0 Number of participants: 5555555555555 2585 ​​Average 0.0 1.3 1.5 1.7 2.3 4.2 3.3 4.2 4.5 7.8 Tight Closing Direction (SD) 0.0 2.5 3.2 2.2 1.9 2.2 1.6 3.9 3.8 3.2 Number of participants: 5555555555555 2586 Average 0.0 -2.1 1.4 3.2 4.2 4.4 4.1 6.7 7.9 8.3 Tight Closing Direction (SD) 0.0 3.1 2.6 1.6 2.3 2.1 1.5 1.8 2.4 4.2 Number of participants: 5555555555555 2600 Average 0.0 0.7 -0.2 1.9 2.9 2.4 2.7 4.8 6.9 5.1 Tight Closing Direction (SD) 0.0 1.2 4.3 3.7 3.5 3.3 3.0 3.0 4.4 3.4 Number of participants: 5555555555555 2605 Average 0.0 1.7 1.6 2.4 4.5 3.8 3.0 5.9 9.1 9.1 Tight Closing Direction (SD) 0.0 2.6 3.2 3.5 2.4 1.9 3.0 4.8 3.1 3.0 Number of participants: 5555555555555 2636 Average 0.0 1.3 1.5 1.7 2.3 4.2 3.3 4.2 4.5 7.8 Tight Closing Direction (SD) 0.0 2.5 3.2 2.2 1.9 2.2 1.6 3.9 3.8 3.2 Number of participants: 5555555555555 2655 Average 0.0 -9.3 -17.4 -25.2 -28.3 -30.6 -36.4 Tight Closing Direction (SD) 0.0 1.9 2.6 2.9 5.7 5.3 7.3 Number of participants: 55555443 2656 Average 0.0 1.7 1.6 2.4 4.5 3.8 3.0 5.9 9.1 9.1 Tight Closing Direction (SD) 0.0 2.6 3.2 3.5 2.4 1.9 3.0 4.8 3.1 3.0 Number of participants: 5555555555555 2657 Average 0.0 1.3 1.5 1.7 2.3 4.2 3.3 4.2 4.5 7.8 Tight Closing Direction (SD) 0.0 2.5 3.2 2.2 1.9 2.2 1.6 3.9 3.8 3.2 Number of participants: 5555555555555 2659 Average 0.0 -9.0 -17.7 -26.6 -28.1 -32.0 -37.2 -39.6 Tightness (SD) direction of closure 0.0 1.0 1.8 2.8 4.7 4.0 3.8 2.5 Number of participants: 5555555542 2660 Average 0.0 -9.3 -17.4 -25.2 -28.3 -30.6 -36.4 Tight Closing Direction (SD) 0.0 1.9 2.6 2.9 5.7 5.3 7.3 Number of participants: 55555443 2668 Average 0.0 -0.9 0.3 2.3 2.4 1.1 0.1 1.5 2.8 3.8 Tight Closing Direction (SD) 0.0 3.2 2.9 1.9 2.6 2.8 2.8 3.3 3.3 5.1 Number of participants: 5555555555555 2669 Average 0.0 -1.5 -0.8 -0.9 1.9 1.6 3.8 3.0 3.9 3.1 Tight Closing Direction (SD) 0.0 1.9 5.0 4.8 3.2 2.0 2.5 3.2 1.8 1.1 Number of participants: 5555555555555 2670 Average 0.0 -9.0 -17.7 -26.6 -28.1 -32.0 -37.2 -39.6 Tightness (SD) direction of closure 0.0 1.0 1.8 2.8 4.7 4.0 3.8 2.5 Number of participants: 5555555542 2671 Average 0.0 -9.3 -17.4 -25.2 -28.3 -30.6 -36.4 Tight Closing Direction (SD) 0.0 1.9 2.6 2.9 5.7 5.3 7.3 Number of participants: 55555443 2672 Average 0.0 -0.9 0.3 2.3 2.4 1.1 0.1 1.5 2.8 3.8 Tight Closing Direction (SD) 0.0 3.2 2.9 1.9 2.6 2.8 2.8 3.3 3.3 5.1 Number of participants: 5555555555555 Table 2. (Continued; Days 11-21) The compound on study day 11 12 13 14 15 16 17 18 19 20 21 2384 Average -0.7 4.1 1.9 -1.8 -3.4 -4.1 -1.6 -0.5 0.7 2.6 2.0 Tight Closing Trend (SD) 17.2 15.4 6.6 10.0 9.6 8.5 9.0 8.4 8.1 7.7 9.5 Number of participants: 555555555555555 2388 Average Tight closure direction (SD) Number of participants 2559 Average Tight closure direction (SD) Number of participants 2560 Average 7.9 9.7 10.0 10.5 7.7 9.4 10.8 12.5 12.3 12.2 13.6 Tight Closing Direction (SD) 5.6 6.2 6.2 4.0 2.4 3.6 3.8 3.1 3.0 3.1 3.8 Number of participants: 555555555555555 2568 Average 4.5 6.0 8.3 11.2 12.2 12.4 11.5 13.6 13.2 11.3 11.4 Tight Closing Direction (SD) 3.1 3.5 4.2 3.5 4.7 7.3 8.1 6.9 4.9 3.6 3.5 Number of participants: 555555555555555 2571 Average 10.6 12.5 13.0 13.2 14.1 15.2 15.9 13.6 13.7 15.2 16.0 Tight Closing Direction (SD) 2.8 2.2 2.3 2.8 3.4 3.4 2.7 1.6 0.9 1.8 2.2 Number of participants: 555555555555555 2585 ​​Average 7.7 8.0 7.9 8.0 7.9 9.4 9.3 9.8 10.5 11.4 12.0 Tight Closing Direction (SD) 2.4 3.3 3.6 2.3 2.5 2.9 1.8 3.2 2.5 3.3 2.4 Number of participants: 555555555555555 2586 Average 7.9 9.7 10.0 10.5 7.7 9.4 10.8 12.5 12.3 12.2 13.6 Tight Closing Direction (SD) 5.6 6.2 6.2 4.0 2.4 3.6 3.8 3.1 3.0 3.1 3.8 Number of participants: 555555555555555 2600 Average 4.5 6.0 8.3 11.2 12.2 12.4 11.5 13.6 13.2 11.3 11.4 Tight Closing Direction (SD) 3.1 3.5 4.2 3.5 4.7 7.3 8.1 6.9 4.9 3.6 3.5 Number of participants: 555555555555555 2605 Average 10.6 12.5 13.0 13.2 14.1 15.2 15.9 13.6 13.7 15.2 16.0 Tight Closing Direction (SD) 2.8 2.2 2.3 2.8 3.4 3.4 2.7 1.6 0.9 1.8 2.2 Number of participants: 555555555555555 2636 Average 7.7 8.0 7.9 8.0 7.9 9.4 9.3 9.8 10.5 11.4 12.0 Tight Closing Direction (SD) 2.4 3.3 3.6 2.3 2.5 2.9 1.8 3.2 2.5 3.3 2.4 Number of participants: 555555555555555 2655 Average Tight closure direction (SD) Number of participants 2656 Average 10.6 12.5 13.0 13.2 14.1 15.2 15.9 13.6 13.7 15.2 16.0 Tight Closing Direction (SD) 2.8 2.2 2.3 2.8 3.4 3.4 2.7 1.6 0.9 1.8 2.2 Number of participants: 555555555555555 2657 Average 7.7 8.0 7.9 8.0 7.9 9.4 9.3 9.8 10.5 11.4 12.0 Tight Closing Direction (SD) 2.4 3.3 3.6 2.3 2.5 2.9 1.8 3.2 2.5 3.3 2.4 Number of participants: 555555555555555 2659 Average Tight closure direction (SD) Number of participants 2660 Average Tight closure direction (SD) Number of participants 2668 Average 2.8 3.7 6.5 6.2 5.2 4.2 6.0 8.5 8.0 8.6 10.4 Tight Closing Direction (SD) 4.7 5.5 5.4 5.0 3.6 4.9 3.5 3.8 3.0 3.6 2.3 Number of participants: 555555555555555 2669 Average 4.3 7.7 8.0 6.5 7.4 7.9 11.7 7.9 7.4 9.7 13.5 Tight Closing Direction (SD) 2.0 3.7 3.4 1.6 2.3 2.5 4.2 2.4 2.2 1.8 4.6 Number of participants: 555555555555555 2670 Average Tight closure direction (SD) Number of participants 2671 Average Tight closure direction (SD) Number of participants 2672 Average 2.8 3.7 6.5 6.2 5.2 4.2 6.0 8.5 8.0 8.6 10.4 Tight Closing Direction (SD) 4.7 5.5 5.4 5.0 3.6 4.9 3.5 3.8 3.0 3.6 2.3 Number of participants: 555555555555555 Example 5: Kinase testing assays Compound 2384 was subjected to kinase assays (performed at Reaction Biology, Germany) according to the detection method. The assay was performed at a final compound concentration of 10 μM. The 33PanQinase® Activity Assay was used to measure the kinase activity of 340 protein kinases. All kinase assays were performed on 96-cavity FlashPlates™ plates from Perkin Elmer (Boston, MA, USA) with a reaction volume of 50 μL. The reaction mixture was pipetted in four steps in the following order: (1) 10 μL of non-radioactive ATP solution (in H2O); and (2) 25 μL of the assay buffer / [γ-33P]-ATP mixture. (3) 5 μL of the test sample in 10% dimethyl sulfoxide and (4) 10 μL of the enzyme / substrate mixture. The all-protein kinase assay contained 70 mM HEPES-NaOH at pH 7.5, 3 mM MgCl2, 3 mM β-MnCl2, 3 mM sodium orthovanadate, and 1.2 mM DTT, 50 µg / mL PEG20000, ATP (variable amounts, corresponding to the apparent ATP-Km of the kinase concerned), [β-33P]-ATP (approximately 8 × 10⁵ counts per million per lumen), protein kinase, and substrate. All PKC assays (except the PKC-mu and PKC-nu assays) also contained 1 mM CaCl₂, 4 mM EDTA, 5 µg / mL phosphatidylserine, and 1 µg / mL 1,2-diolylglycerol. The CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CAMKK1, CAMKK2, DAPK2, EEF2K, MYLK, MYLK2, and MYLK3 assays contained 1 μg / ml calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays also contained 1 μM cGMP. The DNA-PK assay contained 2.5 μg / ml DNA. The protein kinase reaction mixture was incubated at 30°C for ≥60 minutes. The reaction was stopped with 50 μL of 2% (v / v) H3PO4, and the plates were aspirated and washed twice with 200 μL of 0.9% (w / v) NaCl. The 33Pi incorporation (counting "cpm") was determined using a microplatelet flash counter (Microbeta, Wallac).All protein kinase assays were performed using a BeckmanCoulter Biomek 2000 / SL robotic system. All protein kinases supplied by RBE were expressed in Sf9 insect cells or Escherichia coli as recombinant GST fusion proteins or His-labeled proteins, either as full-length proteins or enzyme-active fragments. All kinases were generated from human cDNA and purified by either affinity chromatography with glutathione or a metal fixative. Affinity tags were removed from several kinases during purification. The purity of the protein kinases was assessed by SDS-PAGE / Coumassi staining, and their identity was confirmed by mass spectrometry. The kinases were produced from external suppliers, purified, and quality-controlled. Sturosporin was used as a positive control. IC50 analysis (calibration from 0.1 nM to 10,000 nM) was also performed on the top 25 protein kinases on compound 2384, following the same procedure. Sturosporin was used as a positive control. Figure 34 shows the results of the kinase assay for compound 2384 according to detection. Kinases that were inhibited by more than 90% are shown in the map as circles, with the size representing the percentage of inhibition. CDK kinases that were inhibited by more than 90% are identified on the left side of the figure. Most of the inhibited kinases (inhibition by more than 90%) belong to the CMGC kinase family, particularly the cyclin-dependent kinases (CDKs), as shown in the kinase map. Specifically, 23 of the 30 most inhibited kinases were CDK / Cyclin compounds. Figures 35 and 36 illustrate the dose-response inhibition of the top 25 selected kinases. This allowed the identification of CDK9 / CycT1, CDK9 / CycK, CDK13 / CycK, and CDK12 / CycK as the primary targets of compound 2384, with IC50 values ​​below 25 nM (lower left quadrant). Example 6: In vitro cytotoxicity assays in the presence of a bivonedistat inhibitor for needle-assisted protein modification The cytotoxicity of the detection compounds was evaluated in vitro in the BT-474 breast cancer cell line and the KB HPV-associated cervical cancer cell line, in the presence or absence of the non-cytotoxic needle-trigger inhibitor bivonedistat. Needle-trigger protein modification is the process by which the ubiquitin-like protein NEDD8 catalyzes the degradation of the CycK protein via a ubiquitin-like pathway. 8000 cells (BT-474) or 3000 cells (KB) were seeded in plates containing 96 cavities and incubated at 37°C for 24 hours. Serial dilutions of the tested compound, previously dissolved in the culture medium, were added, and incubation was carried out at 37°C for 5 days in the presence or absence of 400 nM bivonedistat. MTT (5 mg / mL in phosphate-buffered saline, 20 μL, Sigma-Aldrich) was added to the cavities, and incubation continued for 1 to 4 hours at 37°C. The culture medium was then carefully removed, and the cavity contents were homogenized using acidic isopropanol. Alternatively, cell viability was determined using cell-titer glo® reagent (Promega). Absorption values ​​were measured on a microplate reader using a wavelength of 570 nm (with a reference wavelength of 690 nm). IC50 concentration values ​​were determined compared to untreated control cells using an inhibitory dose-response curve fitting (GraphPad Prism 9). Bivonedistat (catalog number HY-70062) was purchased from MedChemExpress (China). Figures 37-44 and 45-52 show that the cytotoxic property of the invention compounds is strongly inhibited by bivonedistat in the BT-474 (Figures 37-44) and KB (Figures 45-52) cell lines, confirming that the main mechanism of action of cytotoxicity is the molecular glue degradation of CycK. Example 7: In vitro mechanistic studies of compound 2384 contained in the invention Determining the amount of protein using Western blot One x 10⁶ JIMT-1 cells were seeded in 3 mL of DMEM / FBS at a 90:10 (v / v) ratio in 6-well plates and incubated overnight. The cells were treated with the patent compound 2384 with or without the proteasome inhibitor MG-132 (MedChemExpress, catalog no. HY-13259) for 2 hours. The cells were collected, and the protein was extracted using complete RIPA buffer (regulated RIPA buffer, 1 mM DTT, 1 mM NaF, and 100 mM sodium orthovanadate, phosphatase inhibitor solution and protease inhibitors) for 1 hour on ice. The extract was centrifuged for 15 minutes at 12,000 g at 4°C. The proteins were mixed with 4x buffered Laemmli Sample solution (Bio-Rad), heated at 95°C for 5 minutes, and separated by SDS PAGE (PROTEAN TGX Stain-Free Gels, Bio-Rad). The proteins were then transferred to a PVDF membrane (iBlot®2 PVDF kits, Invitrogen) using an iBlot2 device (Invitrogen) and blocked using TBS buffer (Intercept® blocking buffer, LI-COR Biosciences).Primary antibodies were incubated overnight at 4°C, and secondary antibodies (infrared dyes from LI-COR Biosciences) for 1 hour at room temperature. The primary antibodies used were anti-CycK (catalog number A301-939A, Bethyl Laboratories, 1:1000 dilution) and anti-beta-actin (catalog number A5441, Sigma-Aldrich, 1:5000 dilution). Membranes were scanned using a c500 imaging system (Azure Biosystems), and densitometric quantification was performed using ImageJ software. Protein levels were assayed using beta-actin. RT-qPCR One x 10⁶ JIMT-1 cells were seeded in 3 ml of DMEM / FBS at a 90:10 (v / v) ratio in 6-well plates and incubated overnight. The cells were treated with the patent compound 2384, CR8 (a known molecular glue depletor that depletes CycK), or the proteasome inhibitor MG-132 (MedChemExpress, catalog no. HY-13259) for 2 hours. RNA was extracted using the QIAamp RNeasy Mini Kit (catalog no. 74106, Qiagen) according to the manufacturer's protocol. Reverse transcription was performed using the SuperScripr™IV reverse transcriptase (catalog no. LT02241, Invitrogen). Quantitative polymerase chain reaction was performed using No ROX Sybr Master Mix in a LightCycler 480 Real-Time PCR system (from Roche Life Science). The forward (CACTATGATACCCTGGCAACTGG) and backward (CAGAAAGAGGCAACAGGCTCCT) primers for Cyclin K were purchased from Eurogentec. Gene expression was assayed using the 28S ribosome as a persistence gene. Assessing cell cycle arrest 10⁶ × 1 JIMT-1 cells were seeded in 3 mL of DMEM / FBS at a 90:10 (v / v) ratio in 6-well plates and incubated overnight. The cells were then treated with compound 2384 (as described in the invention) or with CR8 for 24 hours. The cells were then collected and washed three times with phosphate-buffered saline (PBS). They were resuspended in 300 µL of propidium iodide working solution (0.05 mg / mL) and incubated for 45 minutes at 4°C in the dark. Analysis was performed using a BD Fortessa flow cytometer controlled by BD FACSDiva software (BD Biosciences), and the data were analyzed using FlowJo software (BD Biosciences). Figures 53 and 54 below show that exposure of cells to compound 2384 of the invention or the known comparator of the CycK molecular glue lysate (at a final concentration of 1 μM) resulted in a decrease in CycK protein content (Figure 53) but not at the level of CycK mRNA (Figure 54). THZ-531, a CDK12 inhibitor, had no effect on CycK protein content at this 1 μM concentration (Figure 53). Combination with the proteasome inhibitor MG-132 restored the cycK protein content (Figure 53). CycK degradation was also evaluated using decreasing doses of compound 2384 in the invention or the comparator CR8 (Figure 55). Treatment of JIMT-1 cells for 2 hours with compound 2384 at a concentration of 10 nM resulted in complete CycK degradation, whereas no CycK was observed with CR8 at this dose. Complete CycK degradation by CR8 requires concentrations between 100 and 500 nM, indicating that the minimum effective dose of compound 2384 for CycK degradation is approximately 10 times lower than that of CR8, which explains its superior cytotoxicity in vitro. Cell cycle analysis using propidium iodide (PI) showed G2 / M phase arrest after 24 hours of treatment with compounds 2384 at low and high doses (2, 5, 10, and 50 nM), whereas treatment with CR8 at 2, 5, and 10 nM had no effect on the cell cycle (Figures 56 and 57). Treatment with CR8 at 50 nM was necessary to induce G2 / M phase arrest. This observation further contributes to explaining the superior cytotoxicity of compound 2384 compared to compound CR8. The examples above show that the detection compounds act as molecular glue solvents for CycK. Example 8: Negative permeability assessment by PAMPA Parallel-fabricated membrane permeability assays (PAMPA) were performed using the PAMPA Explorer kit (pION Inc., USA) and the dual-reservoir protocol (Avdeef et al., 2005). Concentrated solutions of the invention compounds were prepared in dimethyl sulfoxide (DMSO) at a final concentration of 10 mM. Each stock solution was diluted to 50 µM in Prisma HT buffer at pH 7.4 (pION) in the presence of 10% methanol (v / v). 200 µM of this diluted solution was added to each of the donor plate cavities in five copies. A polyvinylidene fluoride (PVDF, 0.45 μM) filtration membrane was coated on the receiver plate with 5 μL of gastrointestinal lipid composition (GIT-0, pION), and 200 μL of receiver bank buffer solution (ASB, pION) was added to each lumen of the receiver plate, along with 10% (v / v) methanol. The receiver filter plate was carefully placed on top of the donor plate to form a sandwich. The sandwich was incubated at 25°C for 5 hours at 300 rpm.The UV-Vis spectra of the solutions in the blank, reference, acceptor, and donor plates were measured using a Tecan Infinite 200 PRO M Nano Plus microplate reader. For each compound, the apparent transmittance values ​​(Papp(10⁻⁶ cm / s)) were calculated using PAMPA Explorer version 3.6 (pION). Ketoprofen was used as a non-transmitting negative control, and verapamil was used as a transmitting positive control. Table 3 below shows the apparent permeability (Papp) values ​​(10⁻⁶ cm / s) of the compounds tested for the invention. The compounds exhibited a continuous series of negative permeability potentials, ranging from zero (compound 2585) to moderate (compound 2636) to high (compound 2671). High apparent permeability (Papp) values ​​are associated with increased negative permeability across the gastrointestinal tract, the blood-brain barrier, and the skin, and with increased intratumoral drug diffusion (the incidental effect). Table 3: Apparent Permeability Values ​​(Papp(10⁻⁶ cm / s)) for the Invention's Compounds Papp compound (10⁻⁶ cm / s) standard error 2384 84 5 2560 135 18 2568 88 16 2571 149 13 2585 ​​<0.3 Not available 2600 90 4 2605 112 6 2636 67 4 2655 125 5 2668 164 7 2670 132 6 2671 176 2 Verapamil 141 9 Ketoprofen 0.4 0.1 Example 9: MDR1 / BCRP substrate Outflow substrate assays for MDR1 and BCRP were performed in MDCK-MDR1 and MDCK-BCRP models in vitro (Preadyport™, Solvo Biotech) at Symeres (Netherlands). The invention compounds (donor cavity concentration 5 μM) were incubated in a Predyport 24-transwell monolayer system using Predyport's recommended pH 7.4 buffer solution (donor and acceptor cavities). After 60 minutes of incubation (without shaking), the samples were collected and resuspended in three times their volume of cold 66% acetonitrile. The samples were stored at -20°C until thawed, then centrifuged and analyzed by LC-MS. Quinidine was used as a positive control for the MDR1 assay, and prazosin as a positive control for the BCRP assay. Exatecan, which is not a known substrate for MDR1, was used as a control. The residual dimethyl sulfoxide content of the concentrated solutions of the compounds was less than 1% (v / v). The analysis was performed twice.The quantity of tested compounds in the donor or receiver chamber is determined using LC / MS relative peak areas (samples of the initial incubation solutions are used as single-point calibrators), without any added standard samples. The data are used to estimate apparent permeability (Papp) and calculate the outflow ratio. Table 4 below shows that the invention compounds exhibited varying levels of MDR1 outflow pump sensitivity. MDR1 is a protein found in the cancer cell membrane that pumps anticancer drugs out of cancer cells, rendering the cell drug-resistant. The Papp(10⁻⁶ cm / s) B (receptor = basal lateral) to A (donor = apical) ratio reflects the compounds' ability to be pumped out of the tumor, and as such, a low Papp B⁻A value is useful in the context of oncology. The B⁻A outflow ratio reflects the overall ability of the compounds to enter cancer cells expressing MDR1 (the balance between passive cell entry A⁻B and tumor pumpability B⁻A). Table 5 below shows that the patented compounds exhibited varying levels of BCRP outflow pump sensitivity. BCRP, like MDR1, is a protein found in the cancer cell membrane that pumps anticancer drugs out of cancer cells, rendering the cell drug-resistant. This multidrug-resistant protein is particularly expressed in breast and lung cancers. The B / A outflow ratio reflects the overall ability of the compounds to enter cancer cells expressing BCRP (the balance between passive cell entry ability AB and tumor pumpability BA). This example illustrates that the invention compounds exhibited varying levels of MDR1 and BCRP efflux potential. For instance, compounds 2655, 2600, and 2605 showed low levels of MDR1 and BCRP efflux potential, and as such, could be particularly suitable for treating multidrug-resistant tumor types (treating patients who have acquired resistance to first / second-line chemotherapy). Table 4: Apparent MDR1 Permeability Values ​​Papp(10⁻⁶ cm / s) and Flow Rate of Invention Compounds Compound Papp (10⁻⁶ cm / s) A (donor) to B (recipient) Papp (10⁻⁶ cm / s) B (recipient) to A (donor) Flow ratio B / A 2655 5.13 26.9 5.25 Exatecan 2.28 16.7 7.31 2605 4.05 54.5 13.44 2600 2.05 59.3 28.86 2668 1.36 56.4 41.60 2671 0.99 43.2 43.68 2670 < 0.50* 23.5 Not available 2560 < 0.70* 26.6 Not available 2571 0.59 64.2 108.24 2636 < 12.9* 30.8 Not available 2585 ​​< 3.4* 34.0 Not available 2384 < 0.25* 36.9 Not available 2568 < 0.54* 40.5 Not available *Based on the minimum measurable quantity (LLOQ) for the LC-MS quantification method Table 5: Apparent permeability values ​​of BCRP Papp (10⁻⁶ cm / s) and flow ratio of the patent compounds Compound Papp (10⁻⁶ cm / s) A (donor) to B (recipient) Papp (10⁻⁶ cm / s) B (recipient) to A (donor) Flow ratio B / A 2605 30.9 40.5 1.31 2600 22.4 47.1 2.10 2655 11.1 38.7 3.47 2671 10.1 46.0 4.54 2560 7.53 37.2 4.94 2670 5.02 29.8 5.93 2636 3.00 18.6 6.21 2668 10.2 71.0 6.99 2384 5.49 50.7 9.24 Exatecan 1.43 17.6 12.3 2571 7.09 91.4 12.9 2568 2.52 59.5 23.6 2585 ​​1.75 49.0 27.9 Reference to drawings Figure 1 A - Cell survival (%) B - The drug (nanomolar) Figure 2 A - Cell survival (%) B - The drug (nanomolar) Figure 3 A - Cell survival (%) B - The drug (nanomolar) Figure 4 A - Cell survival (%) B - The drug (nanomolar) Figure 5 A - Cell survival (%) B - The drug (nanomolar) Figure 6 A - Cell survival (%) B - The drug (nanomolar) Figure 7 A - Cell survival (%) B - The drug (nanomolar) Figure 8 A - Cell survival (%) B - The drug (nanomolar) Figure 9 A - Cell survival (%) B - The drug (nanomolar) Figure 10 A - Cell survival (%) B - The drug (nanomolar) Figure 11 A - Cell survival (%) B - The drug (nanomolar) Figure 12 A - Cell survival (%) B - The drug (nanomolar) Figure 13 A - Cell survival (%) B - The drug (nanomolar) Figure 14 A - Cell survival (%) B - The drug (nanomolar) Figure 15 A - Cell survival (%) B - The drug (nanomolar) Figure 16 A - Cell survival (%) B - The drug (nanomolar) Figure 17 A - Cell survival (%) B - The drug (nanomolar) Figure 18 A - Cell survival (%) B - The drug (nanomolar) Figure 19 A - Cell survival (%) B - The drug (nanomolar) Figure 20 A - Cell survival (%) B - The drug (nanomolar) Figure 21 A - Cell survival (%) B - The drug (nanomolar) Figure 22 A - Cell survival (%) B - The drug (nanomolar) Figure 23 A - Cell survival (%) B - The drug (nanomolar) Figure 24 A - Cell survival (%) B - The drug (nanomolar) Figure 25 A - Cell survival (%) B - The drug (nanomolar) Figure 26 A - Cell survival (%) B - The drug (nanomolar) Figure 27 A - Cell survival (%) B - The drug (nanomolar) Figure 28 A - Cell survival (%) B - The drug (nanomolar) Figure 29 A - Cell survival (%) B - The drug (nanomolar) Figure 30 A - Cell survival (%) B - The drug (nanomolar) Figure 31 A - Cell survival (%) B - The drug (nanomolar) Figure 32 A - Cell survival (%) B - The drug (nanomolar) Figure 33 A - Cell survival (%) B - The drug (nanomolar) Figure 34 A - Compound 2384 B - Human Kinome C - Other E - CDK inhibitory kinases C - Inhibitory kinases (inhibition >90%) in a group of 340 kinases Figure 35 A - Sterosporin B - Example C - Kinase D - IC50(M) Figure 36 A - Kinase inhibition [dose response] b - IC50 value of staurosporin (nanomolar) C - IC50 value of compound 2384 (nanomolar) Figure 37 A - + Bivonedistatin B - BT-474 cell line C - Cell survival (%) د - الحمولة (نانومولار) الشكل 38 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 39 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 40 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 41 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 42 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 43 أ - + بيفونيديستات ب - خط خلايا BT-474 ج - بقاء الخلية (%) د - الحمولة (نانومولار) الشكل 44 أ - + بيفونيديستات B - BT-474 cell line C - Cell survival (%) D - Load (nanomolar) Figure 45 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 46 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 47 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 48 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 49 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 50 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 51 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 52 A - Unladen load b - + bifonistat C - Cell survival (%) D - Load (nanomolar) Figure 53 A - Cyclen K b-beta-actin Figure 54 A - Expression of cyclin K mRNA b - Relative expression of mRNA versus NT (calibrated to 28S) Figure 55 A - Cyclen K b-beta-actin Figure 56 A - JIMT-1 cell cycle b - Cells (%) C - CR8 compound (nanomolar) Figure 57 A - JIMT-1 cell cycle b - Cells (%) C - Compound 2384 (nanomolar)

Claims

1. Compound with formula (I): (I) where the halogen is a halogen atom, preferably Br; R1 is chosen from the group consisting of H and the alkyl C1-C6, and the alkyl mentioned is optionally substituted; R2 is chosen from the group consisting of C1-C20 alkyl, C1-C20 heteroalkyl, an aryl containing 6 to 10 cyclic atoms, C3-C8 cycloalkyl, a heterocycloalkyl containing 3 to 10 cyclic atoms, a heteroaryl containing 5 to 10 cyclic atoms, any combination of the above, and the aforementioned alkyl, a heteroalkyl, an aryl, a cycloalkyl, a heteroaryl, and a heterocyclic group that is optionally substituted, preferably by one or more substituents chosen from the group consisting of -OH, and=O, C1-C12 alkyl, C1-C12 heteroalkyl, and C3-C6 cycloalkyl. A heterocyclyl group contains 5 to 10 cyclic atoms, an aryl group contains 6 to 10 cyclic atoms, a heteroaryl group contains 5 to 10 cyclic atoms, and -NR'R''; R' and R'' areTheir selection independently from H and C1-C6 alkyl; Alternatively, R1 and R2, along with the N atom to which they are bonded, form a heterocycloalkyl containing 3 to 10 heteroatoms, or a heteroaryl containing 5 to 10 cyclic atoms. The aforementioned heterocycloalkyl is selectively substituted, preferentially by one or more substituents chosen from -OH, =O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, a heterocyclyl group containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 homoatoms, a heteroaryl containing 5 to 10 cyclic atoms, and -(C1-C12 alkyl)-(cycloalkyl cycloalkyl C3-C8), -(alkyl C1-C12)-(heterocycloalkyl containing 3 to 10 cyclic atoms), -(alkyl C1-C12)-(heterocyclic aryl containing 5 to 10 cyclic atoms), -(alkyl C1-C12)-(aryl containing 6 to 10 cyclic atoms), -(cycloalkyl C3-C8)-(heterocyclic C1-C12), (heterocycloalkyl containing 3 to 10 atoms(cyclic)-(heteroalkyl C1-C12), (heteroalkyl aryl containing 5 to 10 cyclic atoms)-(heteroalkyl C1-C12), and (aryl containing 6 to 10 cyclic atoms)-(heteroalkyl C1-C12), and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl; and pharmaceutically acceptable salts and solvates thereof.

2. A compound bearing the formula (I) according to protection element 1, where R2 is chosen from the group consisting of a C1-C12 heteroalkyl, an aryl containing 6 to 10 cyclic atoms, a C3-C8 cycloalkyl, a heterocycloalkyl containing 3 to 10 cyclic atoms, -(C1-C12 alkyl)-(C3-C8 cycloalkyl), -(C1-C12 alkyl)-(a heterocycloalkyl containing 3 to 10 cyclic atoms), a mentioned alkyl, a heteroalkyl, an aryl, a cycloalkyl, and a heterocycloalkyl. One or more substitutions are chosen from the group consisting of -OH, O=O, C1-C12 alkyl, heterocyclic alkylheteroalkyl C1-C12, cycloalkyl C3-C6, a heterocyclyl group containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl.

3. A compound bearing formula (I) according to protection element 1, where R1 and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic alkyl group containing 3 to 10 cyclic atoms and including at least two N atoms, where the heterocyclic alkyl is optionally substituted by one or more substituents preferred from the C1-C12 heteroalkyl, and a heterocyclyl group containing 5 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from the H and C1-C6 alkyl.

4. The compound bearing formula (I) according to any of the protection elements 1 to 2, where Hal is Br, R1 is H, and R2 is a cycloalkyl C3-C8, replaced by -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl.

5. The compound bearing formula (I) according to protection element 1, where the compound is a carrierFor formula (II): (II) where L is a bond chosen from a bond, and C1-C20 alkylene, C1-C20 heteroalkylene, arylene containing 6 to 10 cyclic atoms, C3-C8 cyclic alkylene, heteroalkylene containing 3 to 10 atoms, heteroarylene containing 5 to 10 cyclic atoms, any combination of the above, and the aforementioned alkylene, heteroalkylene, arylene, cyclic alkylene, heteroarylene, and heteroalkylene, which is optionally substituted, preferentially by one or more substituents from the group consisting of -OH, and=O, C1-C12 alkyl, and C1-C12 heteroalkyl. The cycloalkyl C3-C6, a heterocyclyl group consisting of 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from the H and alkyl C1-C6, R3 is chosen from the group consisting of H and alkyl C1-C6, and R4 is chosen from the group consisting of H and alkyl C1-C6.

6. The compound bearing formula (I) according to protection element 1, where the compound bearing formula (III): (III) whereRing A is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a heteroaryl mentioned and a heterocycloalkyl is optionally substituted, preferentially by one or more substituents chosen from the group consisting of -OH, and=O, and C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, a heterocycloalkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; and R' and R'' are chosen independently from H and C1-C6 alkyl; L is a bond chosen from a bond, a C1-C12 alkylene, a C1-C12 heteroalkylene, an arylene containing 6 to 10 cyclic atoms, a C3-C8 cyclic alkylene, a heteroalkylene containing 3 to 10 atoms, a heteroarylene containing 5 to 10 cyclic atoms, any combination of the above, and the aforementioned alkylene, heteroalkylene, arylene, cyclic alkylene, heteroarylene, and a heteroalkylene substituent.Optionally, and preferred by one or more substituents from the group consisting of -OH, and=O, and C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, a heterocyclyl group consisting of 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl; R3 is chosen from the group consisting of H and C1-C6 alkyl, R4 is chosen from the group consisting of H and C1-C6 alkyl.

7. The compound bearing the formula (I) according to protection element 1, where the compound bears the formula (IV): (IV) where ring A is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a heteroaryl mentioned and a heterocycloalkyl is optionally substituted, preferably by one or more substituents chosen from the group consisting of -OH, and=O, and C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, and a heterocycloalkyl containing 5 to 10 cyclic atoms;Aryl contains 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl. Ring B is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a heteroaryl mentioned and a heterocycloalkyl is optionally substituted, preferably by one or more substituents chosen from the group consisting of -OH, and=O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, a heterocycloalkyl containing 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and the alkyl C1-C6, where L is a bond chosen from a bond, and C1-C12 alkylene, C1-C12 heteroalkylene, arylene containing 6 to 10 cyclic atoms, C3-C8 cyclic alkylene, heteroalkylene containing 3 to 10 atoms, heteroarylene containing 5 to 10 cyclic atoms, and any combination of the above, and the aforementioned alkylene, and heteroalkylene.Arylene, cyclic alkylene, heteroarylene, heterocyclic alkylene that is selectively substituted, and preferred by one or more substituents from the group consisting of -OH, and=O, C1-C12 alkyl, heteroalkyl C1-C12 alkyl, cycloalkyl C3-C6 alkyl, a heterocyclyl group consisting of 5 to 10 cyclic atoms, an aryl containing 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are selected independently from H and C1-C6 alkyl; and R3 is selected from the group consisting of H and C1-C6 alkyl.

8. The compound bearing the formula (I) according to protection element 1, where the compound bears the formula (V): (V) where ring B is a heteroalkyl containing 3 to 10 cyclic atoms, or a heteroaryl containing 5 to 10 cyclic atoms, and a heteroaryl mentioned and a heterocycloalkyl chosen, preferably by one or more substituents chosen from the group consisting of -OH, =O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, and heterocycloalkylThe heterocycloalkyl contains 5 to 10 cyclic atoms, the aryl contains 6 to 10 cyclic atoms, and -NR'R''; R' and R'' are chosen independently from H and C1-C6 alkyl groups; L is a bond chosen from a bond, C1-C12 alkylene, C1-C12 heteroalkylene, arylene containing 6 to 10 cyclic atoms, C3-C8 cyclic alkylene, heteroalkylene containing 3 to 10 atoms, heteroarylene containing 5 to 10 cyclic atoms, any combination of the above, the aforementioned alkylene, heteroalkylene, arylene, cyclic alkylene, heteroarylene, heteroalkylene, and heteroalkylene that is selectively substituted, preferentially by one or more substituents from the group consisting of -OH, and=O, C1-C12 alkyl, C1-C12 heteroalkyl, C3-C6 cycloalkyl, and a heterocyclic group. The heterocyclyl group consists of 5 to 10 cyclic atoms, and the aryl group contains 6 to 10 cyclic atoms. The -NR'R'', R'', and R''' are chosen independently from the H and C1-C6 alkyl groups; and R3 is chosen from the group consisting of the H and C1-C6 alkyl groups.

9. The compound is classified according to the protection element 1, whereThe compound with formula (I) is chosen from the following:

10. The compound according to protection element 9, where Hal is Br.

11. The compound according to protection element 1, where the compound is chosen from the following:

12. The compound according to protection element 1, where the compound is chosen from the following:

13. A pharmaceutical composition consisting of a compound according to any of protection elements 1 to 12 and a pharmaceutically acceptable carrier.

14. Formulated according to any of the protection factors 1 to 12, or the pharmaceutical composition according to protection factor 13, for use as a medicine.

15. Formulated according to any of the protection factors 1 to 12, or the pharmaceutical composition according to protection factor 13, for use in the treatment of cancer or inflammatory disease.